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ABBREVIATIONS 
ACE  Angiotensin-converting enzyme 
ADE  Adverse drug effect 
ADR  Adverse drug reaction 
ANF  Atrial natriuretic factor 
ATC  Anatomical Therapeutic Chemical classification system 
Clhep  Hepatic clearance 
Cli  Intrinsic hepatic clearance 
CNS  Central nervous system 
COX  Cyclooxygenase 
CYP  Cytochrome P450 
DDI  Drug-drug interaction 
E  Hepatic extraction of a drug 
EPS  Extrapyramidal symptoms 
Fu  Fraction unbound 
GABA  γ-Aminobutyric acid 
GFR  Glomerular filtration rate 
GW  Geriatric ward 
ICD-10  International Classification of Diseases, tenth revision 
ICH  International Conference on Harmonization 
ICU  Intensive care unit 
INR  International normalized ratio 
LMWH  Low-molecular-weight heparin 
MW  Medical ward 
NSAID  Nonsteroidal anti-inflammatory drug 
OTC drugs  Over-the-counter drugs 
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pAI  Potentielle Arzneimittelinteraktion 
pDDI  Potential drug-drug interaction 
PGE2  Prostaglandin E2 
Pgp  P-glycoprotein 
PIM  Potentially inappropriate medication 
PUM  Potentiell ungeeignetes Medikament 
Q  Liver blood flow 
SIADH  Syndrome of inappropriate antidiuretic hormone secretion 
SSRI  Selective serotonin reuptake inhibitor 
UAW  Unerwünschte Arzneimittelwirkung 
WHO  World Health Organization 
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SUMMARY 
Because of demographic aging the proportion of elderly persons in the population is 
increasing, especially in industrialized countries. Increasing age is associated with a 
higher prevalence of comorbidities possibly necessitating pharmacotherapy. Elderly 
persons are not only treated with more drugs than younger ones, but they are also 
more vulnerable to adverse drug reactions (ADRs). The aim of the thesis was to 
elucidate potential risk factors that increase the risk for ADRs in the elderly with the 
purpose to improve safety of medical treatment. First, the literature was reviewed in 
order to get an overview on the potential risk factors already known. It has been 
shown that not only physiological changes that affect pharmacokinetic and/or 
pharmacodynamic effects of drugs, but also specific drugs and drug classes may 
increase the risk for ADRs. Two studies were then performed to evaluate specific 
aspects of drug prescribing, which may enhance the risk for ADRs. 
In the first study age-specific differences in the prevalence of clinically relevant 
potential drug-drug interactions (pDDIs) in ambulatory dyslipidemic patients treated 
with a statin were evaluated. Practitioners from different parts of Switzerland 
collected data for a total of 2’742 patients treated with a statin which attended their 
practice. Medical treatment was screened for clinically relevant pDDIs, defined as a 
DDI that could have had a potential serious outcome, using an interactive electronic 
drug interaction program. The prevalence of clinically relevant pDDIs was 
significantly higher in patients aged ≥75 years than in patients aged ≤54 years 
(18.4% versus 7.9%; p < 0.001). This was ascribed to a higher number of diseases 
(3.5 versus 2.8; p < 0.001) and pharmacologically active substances prescribed (5.8 
versus 3.8; p < 0.001). Beside polypharmacy, also heart failure and arrhythmia have 
been identified as risk factors for pDDIs in elderly patients. The more frequent 
prescription of cardiovascular drugs with a high potential for drug interactions (e.g. 
amiodarone and digoxin) was mainly responsible for the observed increase in statin 
and non statin pDDIs. 
The aim of the second study was to retrospectively evaluate and compare the 
prevalence of potentially inappropriate medication (PIM) use and prescription of 
drugs with strong anticholinergic properties in 800 elderly patients hospitalized on 
general medical or geriatric wards throughout hospital stay. PIMs as defined by the 
Summary 
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Beers criteria and anticholinergic drugs have been associated with a higher risk for 
ADRs in patients aged ≥65 years. At hospital discharge, geriatric patients had a lower 
prevalence of use of PIMs that should generally be avoided than at admission 
(15.9% versus 22.1%; p < 0.05), whereas no difference was observed in medical 
patients. Overall, the three most prevalent inappropriate drugs/drug classes were 
amiodarone, long-acting benzodiazepines and anticholinergic antispasmodics. On 
the other hand, geriatric patients were discharged with a higher prevalence of use of 
PIMs that should be avoided in the presence of specific underlying diseases 
compared to medical patients (23.7% versus 11.7%; p < 0.001). The main reason 
was the higher prescription rate of benzodiazepines to patients with a history of falls 
and syncope. There was neither a difference in the prevalence of patients with 
anticholinergic drugs at admission nor at discharge between medical and geriatric 
patients. Compared with internists, geriatricians appeared to be more aware of PIMs 
that should generally be avoided. However, the results of this study should be 
interpreted with caution, because some of the drugs identified as potentially 
inappropriate may in fact be beneficial when the patient’s individual clinical condition 
is taken into consideration. 
Finally, a patient with lithium intoxication as a result of a drug-drug interaction (DDI) 
with rofecoxib is presented. This 68-year-old woman had several risk factors that 
finally resulted in the clinical manifestation of the DDI, illustrating well the problems of 
pharmacotherapy in the elderly. The already impaired renal function (calculated 
creatinine clearance 40 mL/min) deteriorated after the addition of rofecoxib, a 
selective cyclooxygenase 2 (COX-2) inhibitor. As a consequence, renal clearance of 
lithium was impaired, leading to an accumulation of the drug and symptoms of lithium 
intoxication such as vomiting, hypokinesia and tremor. Selective COX-2 inhibitors 
seem therefore not to be safer than conventional nonsteroidal anti-inflammatory 
drugs concerning their effect on renal function, especially in patients with renal 
insufficiency. 
Depending on the underlying disease, medical treatment with drugs associated with 
a high potential for DDIs and/or ADRs may not always be avoided. Knowledge of the 
potential risk can help to take appropriate measures to lower the probability for an 
adverse outcome, e.g. close monitoring of the patient, dose adjustment or selection 
of an alternative drug. 
Zusammenfassung 
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ZUSAMMENFASSUNG 
Der Anteil älterer Personen in der Bevölkerung nimmt speziell in industrialisierten 
Ländern stetig zu. Höheres Alter ist verbunden mit einer Zunahme von Erkrankungen 
und Einnahme von Medikamenten. Ältere Patienten sind allerdings häufiger von 
unerwünschten Arzneimittelwirkungen (UAW) betroffen. Das Ziel der vorliegenden 
Dissertation war es, Risikofaktoren für UAW bei älteren Patienten näher zu 
untersuchen, um so zu einer höheren Arzneimittelsicherheit beizutragen. In einem 
ersten Schritt wurden in einem Review der bestehenden Literatur mögliche 
Risikofaktoren eruiert. Es zeigte sich, dass nicht nur physiologische Veränderungen, 
welche zu einer Veränderung der Pharmakokinetik und/oder Pharmakodynamik von 
Medikamenten führen können, sondern auch bestimmte Medikamente respektive 
Medikamentengruppen mit einem erhöhten Risiko für UAW assoziiert sind. In einem 
weiteren Schritt wurden zwei Studien durchgeführt, um spezifische Risiken für UAW 
in der Pharmakotherapie älterer Patienten zu untersuchen. 
In der ersten Studie wurden altersabhängige Unterschiede in der Prävalenz von 
klinisch relevanten potentiellen Arzneimittelinteraktionen (pAI) bei 2’742 ambulanten 
dyslipidämischen Patienten mit einer Statin-Therapie untersucht. Als klinisch relevant 
galten Interaktionen, die mit dem Auftreten schwerwiegender UAW verbunden sein 
können. Die Prävalenz klinisch relevanter pAI war signifikant höher in der ältesten im 
Vergleich zur jüngsten Patientengruppe (18.4% versus 7.9%; p < 0.001). Das war auf 
die höhere Anzahl Diagnosen (3.5 versus 2.8; p < 0.001) und verschriebener 
Substanzen (5.8 versus 3.8; p < 0.001) zurückzuführen. Nebst der Polypharmazie, 
wurden auch Herzinsuffizienz und Arrhythmie als Risikofaktoren für pAI bei älteren 
Patienten identifiziert. Die Zunahme an pAI mit und ohne Statinbeteiligung war 
hauptsächlich auf die Verschreibung von kardiovaskulären Medikamenten mit einem 
hohen Interaktionspotential (z.B. Digoxin und Amiodaron) zurückzuführen. 
Ziel der zweiten Studie war es, retrospektiv die Prävalenz der Verschreibung von 
potentiell ungeeigneten Medikamenten (PUM) gemäss Beers Kriterien und 
Medikamenten mit anticholinergen Eigenschaften bei 800 Patienten ≥65 Jahre, 
welche auf medizinischen und geriatrischen Abteilungen hospitalisiert waren, 
während des gesamten Spitalaufenthalts zu erfassen und miteinander zu 
Zusammenfassung 
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vergleichen. Die Prävalenz der Patienten mit PUM, welche generell zu vermeiden 
sind, war bei geriatrischen Patienten bei Austritt im Vergleich zu Eintritt signifikant 
geringer (15.9% versus 22.1%; p < 0.05). Bei medizinischen Patienten war keine 
Abnahme zu verzeichnen. Die drei häufigsten PUM waren in beiden 
Patientengruppen Amiodaron, langwirksame Benzodiazepine und anticholinerge 
Spasmolytika. Im Vergleich zu medizinischen Patienten war die Prävalenz von PUM, 
welche aufgrund gewisser Erkrankungen vermieden werden sollten, bei geriatrischen 
Patienten bei Spitalaustritt signifikant höher (23.7% versus 11.7%; p < 0.001). Dies 
war hauptsächlich auf die Verschreibung von Benzodiazepinen an Patienten mit 
Stürzen oder Synkopen in der Anamnese zurückzuführen. Medizinische und 
geriatrische Patienten unterschieden sich weder bei Eintritt noch bei Austritt in der 
Prävalenz der Verschreibung von anticholinergen Medikamenten. Im Vergleich zu 
Internisten, schienen Geriater Medikamente, welche generell nicht an ältere 
Patienten verschrieben werden sollten, besser zu kennen. Allerdings können 
gewisse Medikamente, welche gemäss Beers Kriterien als potentiell ungeeignet 
definiert wurden (z.B. Amiodaron), durchaus einen Benefit für den Patienten bringen, 
wenn das Risiko individuell für den Patienten abgeschätzt wird. 
Der Fallbericht einer 68-jährigen Patientin zu Lithiumintoxikation als Folge einer 
Interaktion mit Rofecoxib zeigte ein Zusammentreffen verschiedener Risikofaktoren, 
welche letztendlich zur klinischen Manifestation der Interaktion führten. Die Patientin 
hatte bereits eine eingeschränkte Nierenfunktion (Schätzclearance 40 mL/min), 
welche sich nach Gabe von Rofecoxib massiv verschlechterte. In der Folge kam es 
zur Akkumulation von Lithium, welches hauptsächlich renal eliminiert wird, und zum 
Auftreten von Nausea, Erbrechen, Hypokinesie und Tremor. Selektive 
Cyclooxygenase-2 Inhibitoren, wie z.B. Rofecoxib, scheinen demnach bezüglich 
UAW auf die Niere bei Patienten mit bestehender Niereninsuffizienz nicht sicherer zu 
sein als konventionelle nichtsteroidale Antirheumatika. 
Es ist zu beachten, dass bei der Behandlung von Erkrankungen gewisse Risiken für 
UAW nicht zu vermeiden sind, welche von pAI oder dem Medikament selbst 
ausgehen. Dieses Risiko lässt sich allerdings durch geeignete Massnahmen wie 
Dosisanpassung, engmaschige Überwachung des Patienten oder Wahl eines 
anderen geeigneten Medikamentes erheblich reduzieren. 
AIMS OF THE THESIS 
Aims of the thesis 
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The major goal of the thesis was to elucidate potential risk factors for adverse drug 
reactions (ADRs) in elderly patients, with the purpose to contribute to safer drug 
prescribing. The elderly are a growing population especially in industrialized 
countries and it is known that they are at higher risk for adverse effects resulting from 
medical treatment. 
First, the literature was reviewed in order to define potential risk factors for ADRs in 
the elderly resulting from physiological changes as well as from polymorbidity and 
associated polypharmacy. From this overview, two topics were selected to be studied 
more in detail by two individual projects. 
In the first project the association between polymorbidity as a risk factor for 
polypharmacy and consequently also potential drug-drug interactions (pDDIs) that 
may result in ADRs was investigated. The main objective of the study was to 
evaluate differences in the prevalence and risk factors of clinically relevant pDDIs 
with age in ambulatory dyslipidemic patients treated with a statin. Potentially serious 
and clinically relevant pDDIs with and without involvement of a statin were evaluated. 
This patient population was selected because of the high risk for polymorbidity, 
especially for the manifestation of cardiovascular diseases, and therefore also 
polypharmacy with increasing age. Drugs associated with a high risk for pDDIs, but 
often prescribed to elderly patients, were identified. The results of this study may help 
to recognize potentially dangerous drug combinations in order that appropriate 
measures can be taken in the future to minimize the risk for ADRs resulting from 
these drug-drug interactions (DDIs). 
In the second project the prevalence of potentially inappropriate medication (PIM) 
use as defined by the Beers criteria and use of drugs with anticholinergic properties 
was evaluated in hospitalized patients aged ≥65 years. Because of age-related 
physiological changes and impaired homeostatic mechanisms some drugs including 
drugs with anticholinergic properties are associated with a higher risk for ADRs due 
to alterations of their pharmacokinetic and/or pharmacodynamic properties. Such 
drugs should therefore be replaced by safer alternatives in the elderly. Also 
underlying diseases or conditions were considered for the evaluation of 
appropriateness of treatment. The identification of frequently prescribed potentially 
inappropriate and anticholinergic drugs could contribute to the development of 
Aims of the thesis 
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recommendations for safer drug prescribing and selection of alternative drugs. The 
prevalence of use of PIMs and anticholinergic drugs of patients hospitalized to a 
medical and geriatric ward was compared at hospital admission, during 
hospitalization as well as at discharge in order to additionally elucidate the potential 
impact of the specific knowledge of geriatricians considering drug treatment and 
associated problems in elderly patients. 
A case of lithium intoxication in an elderly woman with renal impairment as a result of 
a drug interaction between rofecoxib and lithium was included in the thesis, because 
several of the risk factors for ADRs identified in the review and the two studies 
performed predisposed the patient for the clinical manifestation of ADRs. It 
emphasizes the need to assess the patient’s clinical condition carefully in order to 
avoid ADRs. 
 
INTRODUCTION  
 
PHYSIOLOGICAL CHANGES AND POLYMORBIDITY 
IN THE ELDERLY: 
ASSESSMENT OF THE POTENTIAL RISK 
FOR ADVERSE DRUG REACTIONS 
Introduction: Physiological changes and polymorbidity in the elderly 
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Demographic aging 
The process of demographic aging observed in Switzerland and other industrialized 
countries is mainly caused by a falling in birth rate and a simultaneous increase of life 
expectancy.1,2 While in the year 2000 the proportion of individuals aged ≥65 years 
was 16% it will reach 28% by the year 2050 (figure 1). The oldest old (individuals 
aged ≥85 years) is the fastest growing segment of the older population. In the year 
2000 about 141’400 individuals aged ≥85 years lived in Switzerland (2% of the total 
population) and it is expected that this number will increase to 554’900 inhabitants or 
6.9% of the total population in Switzerland by the year 2050.1 
0
2
4
6
8
10
12
14
16
18
20
2000 2010 2020 2030 2040 2050
Years
%
 
o
f t
o
ta
l p
o
pu
la
tio
n
 
in
 
Sw
itz
er
la
n
d
 individuals aged 65-74 years    individuals aged 75-84 years   
 individuals aged ≥85 years   
Figure 1. Demographic development of the elderly population in Switzerland based on data from the Federal 
Office for Statistics1 according to the reference scenario. 
 
The prevalence of individuals with long term diseases increases with higher age and 
amounts to 66-75% in individuals aged ≥65 years.3 As a consequence healthcare 
costs per inhabitant raise continuously with age.2 Considering only medication costs, 
prescription drugs to individuals aged >65 years accounted for 40% of the medication 
costs in Switzerland in the year 2002.2 This is similar to findings in other 
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industrialized countries, where elderly patients constitute only 13-20% of the 
population, but consume 30-50% of the drugs prescribed.3-5 
The administration of drugs may be related with adverse drug events (ADEs) or 
ADRs. According to the World Health Organization (WHO) an ADR is defined as any 
noxious and unintended reaction caused by a drug that is used at appropriate human 
doses for prophylaxis, diagnosis or therapy.6 This definition does not include events 
resulting from medication errors, overdosage, and drug abuse, or therapeutic failure 
because of poor adherence, which are defined as ADEs.7 In 80-90% of the cases an 
ADR can be explained by the pharmacological effect of the drug and occurs dose-
dependent.7,8 This type of reaction is defined as type A (augmented) reaction. About 
10-20% of the ADRs are not foreseeable and occur normally not dose-dependent 
such as allergic, pseudoallergic or idiosyncratic reactions.7,8 These ADRs are 
classified as type B (bizarre) reactions. It is estimated that ADRs would be the fifth 
leading cause of death in the United States, if they were ranked as a disease by 
cause of death.9 
 
 
Elderly patients at risk for ADRs 
Due to age-related physiological changes, the pharmacokinetics (absorption, 
distribution, metabolism and elimination) and/or the pharmacodynamics of a drug 
may be altered in elderly patients. These changes may be responsible for the more 
frequent occurrence of ADRs in the elderly, if drug therapy is not adapted (figure 2). 
ADRs are responsible for 6-12% of hospital admissions in the elderly.10-12 During 
hospitalization, the risk to experience an ADR is further increased because of the 
administration of multiple drugs during a short period of time and because of 
treatment with drugs associated with a high potential for ADRs used only in a hospital 
setting.13 As a result, up to 61% of elderly patients may experience ADRs of various 
severities during hospital stay.10,13  
Introduction: Physiological changes and polymorbidity in the elderly 
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In addition to age-related physiological changes the prevalence of diseases is also 
increasing with age.14 The presence of multiple diseases is correlated with 
polypharmacy, which is a risk factor for DDIs that may result in ADRs (figure 2). DDIs 
may be classified, according to their underlying mechanism, in pharmacodynamic 
and pharmacokinetic interactions.15 In case of a pharmacokinetic interaction 
absorption, distribution, metabolism or elimination of a drug is altered by another 
drug. Of particular importance is the inhibition or induction of the cytochrome (CYP) 
P450 isozymes in the gut and liver by drugs. This is relevant for substrates whose 
metabolism is mainly dependent on one specific CYP isozyme. But also drugs that 
influence the activity of P-glycoprotein (Pgp) may play an important role.15 Pgp is a 
transporter localized in intestinal epithelial cells, in the liver, kidney and blood brain 
barrier protecting cells from xenobiotics and toxic substances. Drug-induced 
inhibition of Pgp may lead to a substantial increase of the concentration of a Pgp 
 
Figure 2. Age-related impairment of organ function and polymorbidity as primary factors leading to an 
increased risk of adverse drug reactions in the elderly. Some drugs may not be appropriate for elderly patients, 
because of a negative benefit-risk-ratio, or because they may exacerbate underlying diseases. ADR = adverse 
drug reaction; ADE = adverse drug event; pDDI = potential drug-drug interaction. 
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substrate and to dose-dependent ADRs (e.g. inhibition of Pgp-mediated transport of 
digoxin by quinidine). However, most of the DDIs in the elderly are pharmacodynamic 
interactions, resulting in a potentiation (or loss) of the pharmacological effect in a 
direct or indirect way. One example for a direct interaction is the antagonism of the 
opiate effect by naloxone, whereas the increased risk for bleeding due to 
concomitant treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and oral 
anticoagulants is an example for an indirect pharmacodynamic interaction. 
The mean number of diagnoses in the elderly ranges between 2 and 7, and the mean 
number of drugs prescribed between 3 and 14, depending on the patient 
setting.10,13,16 The prevalence of clinically relevant pDDIs increases continuously with 
the number of drugs administered, affecting approximately 40% of the patients if  
≥7 drugs are prescribed concomitantly.16 DDIs are responsible for up to 24% of the 
ADRs observed in the elderly.10,13 
Polypharmacy and various diseases may also affect adherence (figure 2). Poor 
adherence may result in an exacerbation of the underlying disease, ADEs, death and 
an increase in health care costs.17 Between 7-12% of hospital admissions or visits to 
emergency departments because of ADEs result from poor adherence.18-20 It is 
estimated that the prevalence of poor adherence in elderly patients ranges between 
26-59%.20,21 
 
 
Age-related changes in organ functions and body composition 
affecting drug effects 
Body composition 
The distribution of drugs may be altered due to changes in body composition. 
Generally, there is a decrease in muscle mass and total body water and an increase 
in adipose tissue with age.22,23 The relative changes may vary between males and 
females being more accentuated in males. Variations in body composition influence 
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the volume of distribution of drugs. An increase in body fat may increase the volume 
of distribution of lipophilic drugs, as shown for diazepam, and prolong their 
elimination half-life and duration of action.14,24 
Age-related changes in protein binding are not considered to be of great clinical 
importance.25 In the Normative Aging Study, albumin levels decreased by 0.54 g/L 
per decade in healthy men, but mean albumin levels of individuals in the eighth 
decade were still within the normal range, averaging 42.5 ± 2.6 g/L in this study.26 
More important reasons for lower albumin concentrations than age are underlying 
diseases such as liver cirrhosis, neoplasms, heart failure, pulmonary infections 
and/or malnutrition.25,27 Displacement from albumin binding sites, e.g. through 
endogenous substances in patients with severe renal insufficiency, as well as low 
albumin levels, may increase the free fraction of drugs highly bound to albumin (e.g. 
oral anticoagulants, phenytoin, valproate). Since the total (free plus albumin-bound) 
plasma concentration of such drugs is decreased in such situations, the dosage of 
such drugs has to be adjusted according to their clinical effect (e.g. international 
normalized ratio [INR]) or to the free drug concentration.25 
 
Gastrointestinal system 
Gastric emptying seems to be delayed in the elderly, whereas the total 
gastrointestinal transit time is similar to younger adults.28-30 Absorption of most drugs 
is not much affected with increasing age, except for some substances transported by 
active transport mechanisms such as protein-bound vitamin B12 or calcium.27,31-33 
Because of a slowed esophageal peristalsis, drugs ingested orally may remain longer 
in contact with the mucosa and may cause mucosal irritations and possibly ulcers.27 
This may be relevant for the administration of bisphosphonates or other drugs with 
irritant effects on the gastrointestinal mucosa such as potassium tablets. Gastric acid 
secretion seems not to decrease with age, but chronic atrophic gastritis has to be 
considered as pathological condition, leading to the exclusion of patients with this 
disorder.34-36 On the other hand, mucosal protective mechanisms, e.g. mucosal 
prostaglandin concentrations and duodenal bicarbonate secretion, as well as gastric 
mucosal blood flow decrease with age.37-39 As a consequence, the risk for gastric 
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mucosal injury is higher with age, especially for patients treated with NSAIDs.37 
Ibuprofen has generally been associated with the lowest risk, followed by diclofenac 
≈ acetylsalicylic acid < indomethacin < naproxen < piroxicam < ketoprofen.40,41 In 
addition, the risk for gastrointestinal complications following treatment with NSAIDs 
seems to be dose dependent.40,41 
 
Liver 
Liver size and hepatic blood flow both decrease with age.15,42 Hepatic clearance 
(Clhep) for a given drug can be expressed as the product of the blood flow across the 
liver (Q) and the extraction of this drug (E) during its first passage across the liver 
(see formula).43 The hepatic extraction of a drug (E) is dependent on the fraction of a 
drug not bound to serum proteins and the intrinsic hepatic clearance (Cli) that reflects 
the capacity of the liver to metabolize a certain drug. 
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For high extraction drugs (fu x Cli) >> Q and the above equation can be simplified to 
QClhep ≈   
Hepatic clearance for high extraction drugs is therefore limited by the blood flow 
across the liver, and the decline in hepatic blood flow by up to 40% in elderly persons 
require dose adjustment of such drugs (table 1).15,42-44 Hepatic metabolism of drugs 
consists of phase I reactions (e.g. oxidation, hydrolysis, dealkylation, reduction; many 
of them CYP P450-dependent) and phase II reactions (e.g. conjugation, acetylation, 
methylation). While phase II metabolism does not appear to be significantly reduced 
with age, data about phase I metabolism are not consistent.42 In vitro, no relationship 
between age and the activity of various CYP isozymes isolated from microsomal 
preparations from liver resection specimens could be found.15,42,45 On the other hand, 
data from pharmacokinetic studies indicate a reduced clearance of drugs that 
undergo phase I metabolism with age.15,42,46 It can be hypothesized that a reduction 
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in oxygen supply to the CYP system due to age-related alterations in blood flow to 
the liver and diffusion of oxygen to the hepatocytes may be responsible for the 
impairment of phase I metabolism.42,47 It has to be considered that pharmacokinetic 
parameters from in vivo studies can be influenced by many more variables than CYP 
isozymes assessed in vitro, including altered protein binding and volume of 
distribution, extrahepatic metabolism, and comedications.15,44 A reduced activity of 
phase I reactions decreases the hepatic clearance of drugs with a low hepatic 
extraction and can be associated with an increased bioavailability of drugs with a 
high hepatic extraction, as demonstrated for propranolol.48  
 
Table 1. Drugs with high hepatic extraction43 
Drug class Examples of drugs with hepatic extraction ≥60% 
Analgesics Morphine, pentazocine, propoxyphene 
Anthelmintics Praziquantel 
Antianginal agents Isosorbide dinitrate, nitroglycerine 
Anticholinesterases Tacrine 
Antidepressants Dibenzepin, doxepin, imipramine, mianserin, sertraline, 
trimipramine, venlafaxine 
Antihyperlipidemic drugs Fluvastatin, lovastatin 
Antimigraine agents Sumatriptan 
Antineoplastic and immunosuppressive agents Cyclosporine, fluorouracil, idarubicin, mercaptopurine, 
sirolimus, tacrolimus, vinorelbine 
Antiparkinson drugs Bromocriptine, levodopa, selegiline, biperiden 
Antipsychotics Chlorpromazine, chlorprothixene, flupenthixol, quetiapine, 
perphenazine, sulpiride 
Beta-adrenoceptor antagonists Labetalol, metoprolol, propranolol 
Calcium channel blockers Nicardipine, nisoldipine, verapamil 
Histamine H1 receptor antagonists Promethazine 
Hypnotics, sedatives, anxiolytics Buspirone, clomethiazole, midazolam, zaleplon 
Phosphodiesterase inhibitors Sildenafil 
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Heart 
There are several changes in cardiac and vascular structures with age.49,50 However, 
left ventricular end-diastolic volume and ventricular ejection fraction at rest are 
preserved with advancing age, providing adequate organ perfusion.49,51 Elderly 
patients show a poor blood pressure regulation in response to orthostasis.52-54 
Impairment of baroreflex sensitivity and attenuation of the vestibulosympathetic reflex 
with age have been discussed as possible underlying mechanisms.53,54 As a 
consequence, elderly patients are more susceptible to postural hypotension in 
response to drugs that lower arterial blood pressure such as antihypertensive drugs, 
antiparkinson drugs, tricyclic antidepressants and antipsychotics with a high affinity to 
α1-receptors (e.g. clozapine, chlorpromazine, risperidone).55,56 
 
Kidney 
Several reviews about changes in renal function with advancing age have been 
published.57-59 Renal plasma flow and glomerular filtration rate (GFR) generally 
decline with age.57,58 The number of functioning glomeruli declines in the elderly, 
while the number of sclerotic glomeruli increases.57,58,60,61 Because of a loss of 
muscular mass with increasing age and a parallel decrease of urinary creatinine 
excretion, concentration of serum creatinine remains nearly constant with age and is 
therefore not a precise indicator of GFR (see also figure 3).27,57,58,62,63 A widely used 
formula for the estimation of GFR, also recommended by the National Kidney 
Foundation, is the Cockcroft-Gault formula:63,64  
femalesfor85.0)dL/mg(creatinineserum72
)kg(weight)age140((mL/min)clearanceCreatinine ×
×
×−
=  
However, the prediction of the creatinine clearance with the Cockcroft-Gault formula 
may not be accurate in healthy elderly individuals, for whom the creatinine clearance 
may be underestimated, and for malnourished patients.63  
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There is generally a decline in GFR by approximately 0.75 mL/min per year between 
the fourth and the eighth decade of life in healthy individuals, but GFR may remain 
within the normal range.65,66 On the other hand, the mean calculated creatinine 
clearance of 1’837 patients aged ≥70 years admitted to an acute care geriatric 
medical unit was 35 ± 15 mL/min (range 5-115 mL/min), indicating that the 
prevalence of renal impairment may be high in elderly individuals with underlying 
diseases (figure 3).27 Important risk factors for a decline in GFR are hypertension, 
heart failure and/or diabetes mellitus.57,66 The high prevalence of renal impairment in 
elderly patients emphasizes the need to assess renal function and to perform dose 
adaptation of renally eliminated drugs in the elderly (table 2), since renal impairment 
is an important risk factor for ADRs.5,14,57,67 Tubular function of the kidney tends to 
parallel the age-dependent decrease in GFR and may therefore also be 
approximated by calculating creatinine clearance.59  
 
 
Figure 3. Creatinine clearance versus serum creatinine in 1’837 patients aged 70-103 years adapted from Merle 
L et al.27. The bar indicates the normal range of serum creatinine (45-117 µmol/L), whereas the normal range for 
women is 45-93 µmol/L and for men 60-117 µmol/L, respectively. 
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Table 2. Drugs mostly cleared unchanged through the kidney 
Drug class Drugs with a fraction of ≥60% excreted unchanged through 
the kidney 
ACE inhibitors Cilazapril, enalapril, lisinopril, quinapril, ramipril 
Aminoglycosides Amikacin, gentamicin, netilmicin, tobramycin 
Antiallergics Acrivastine, cetirizine, levocetirizine 
Antidiabetics Metformin 
Antiepileptics Gabapentin, levetiracetam, pregabalin, topiramate, vigabatrin 
Antigout agents Oxypurinol (major active metabolite of allopurinol) 
Antimycotics Fluconazole, flucytosine, terbinafine 
Beta-adrenoceptor antagonists Atenolol, esmolol, nadolol, sotalol  
Betalactam antibiotics Penicillins, cephalosporins, others: aztreonam, imipenem, 
meropenem 
Cytostatics Carboplatin, cisplatin, dacarbazine, methotrexate, pemetrexed 
Digitalis glycosides Digoxin 
Fluorochinolons Ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin 
Glycopeptid antibiotics Teicoplanin, vancomycin 
Histamine H2 receptor antagonists Cimetidine, famotidine, nizatidine, ranitidine 
Lithium  
Low-molecular-weight heparins Dalteparin, enoxaparin, nadroparin, tinzaparin 
Opioids Morphine-6-glucuronide (active metabolite of morphine) 
Tetracyclines Tetracycline 
Virostatics Aciclovir, ganciclovir, foscarnet, NRTIs: adefovir, tenofovir 
NRTIs = nucleoside/nucleotide reverse transcriptase inhibitors. 
With advancing age, adaptive mechanisms responsible for water and electrolyte 
homeostasis are impaired.57,58 Dehydration may occur more frequently in the elderly 
because the renal tubular response to arginine vasopressin, a hormone principally 
responsible for the regulation of water balance, is diminished and the perception of 
thirst is decreased.68,69 Especially treatment with diuretics may markedly affect water 
and electrolyte homeostasis and is one of the most common reasons for electrolyte 
disturbances, dehydration and acute prerenal failure in the elderly.3,58 Hyponatremia 
and hyperkalemia occur more frequently in the elderly due to a decrease in plasma 
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renin activity resulting in low aldosterone levels.68,70 Aldosterone regulates sodium 
reabsorption and potassium secretion in the collecting tubule.71 In addition, secretion 
of atrial natriuretic factor (ANF) is increased in the elderly.68,72 ANF is responsible for 
natriuresis and inhibits the renal renin secretion, contributing to a further decrease in 
aldosterone levels. On the other hand, several drugs are associated with 
hyperkalemia, e.g. potassium-sparing diuretics, NSAIDs, angiotensin-converting 
enzyme (ACE) inhibitors, cyclosporine, and tacrolimus.70,71 Serum sodium 
concentrations should be monitored closely when patients are treated with 
substances known to be associated with hyponatremia and/or the syndrome of 
inappropriate antidiuretic hormone secretion (SIADH) such as selective serotonin 
reuptake inhibitors (SSRIs), tricyclic antidepressants, carbamazepine, 
oxcarbazepine, vasopressin and analogues, oxytocin, vinca alkaloids, 
cyclophosphamide, chlorpropamide, tolbutamide, thiazide diuretics, NSAIDs and 
antipsychotics.57,73,74 
 
Central nervous system 
There is a decrease in cholinergic function in the central nervous system (CNS) with 
age, contributing to cognitive impairment and Alzheimer’s disease.75,76 Results from 
post mortem and ante mortem studies in aged humans and patients with Alzheimer’s 
disease, as well as animal experiments, suggest that a loss of cholinergic neurons in 
the basal forebrain, alterations in choline transport and acetylcholine release, and 
muscarinic receptor expression may all contribute to the observed cognitive 
impairment.75 These changes in cholinergic function could explain the higher 
susceptibility of elderly patients to central anticholinergic drug effects resulting from 
treatment with highly anticholinergic drugs such as some of the antipsychotic agents 
(e.g. clozapine, chlorpromazine), tri- and tetracyclic antidepressants, first generation 
histamine H1 receptor antagonists, anticholinergic antiparkinson agents and 
antispasmodics.77 
Regarding benzodiazepines, it is not fully established, if pharmacokinetic and/or 
pharmacodynamic changes lead to the observed higher risk for ADRs in the elderly.33 
Nevertheless, it is suggested that changes in the affinity of benzodiazepines to the  
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γ-aminobutyric acid type A (GABAA) receptor due to age-related alterations in the 
expression of its subunits could influence the effects of benzodiazepines that are 
mediated by distinct GABAA receptor subunits.78 
Dopaminergic neurotransmission in the CNS is involved in many aspects of human 
behavior including motor function, cognitive performance and mood.79 Ascending 
dopaminergic neurons degenerate with age, along with postsynaptic dopamine 
receptors as shown for D1 and D2 receptors in the striatum.80 These changes in 
dopaminergic neurotransmission may contribute to the occurrence of Parkinson’s 
disease, cognitive impairment, and more frequent manifestation of extrapyramidal 
symptoms (EPS) following treatment with conventional antipsychotics in the 
elderly.79-82 It is assumed that a 60-70% occupancy of D2 receptors is required for an 
antipsychotic response.83 On the other hand, a rise above 80% seems to increase 
the incidence of EPS. In comparison with conventional agents, the risk of tardive 
dyskinesia during treatment with atypical antipsychotics is lower, which may be 
explained by a lower D2 occupancy at usual therapeutic doses.83 However, D2 
occupancy increases with the dosage of atypical antipsychotics used.84 Atypical 
antipsychotics are associated with other ADRs than EPS, namely weight gain, 
diabetes, cardiac effects or sexual adverse effects.83 
 
 
Polymorbidity and polypharmacy increasing the risk for ADRs in 
the elderly 
Treatment of cardiovascular diseases and associated risk for ADRs 
The most frequent diagnoses in the elderly are hypertension, ischemic heart disease, 
heart failure, cerebrovascular diseases, atrial fibrillation, and diabetes mellitus.10,85,86 
Age-related changes in vascular and cardiac structures may contribute to the high 
prevalence of cardiovascular diseases observed in the elderly, lowering the threshold 
for the manifestation of rhythm disorders such as atrial fibrillation and heart failure 
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that are induced by other factors.49 For the treatment of cardiovascular diseases, 
often several drugs are needed, predisposing the patients to polypharmacy and 
related problems. In addition, patients with cardiovascular diseases often have 
predisposing risk factors such as type 2 diabetes mellitus and/or hyperlipidemia that 
also require medical treatment and further increase the risk for polypharmacy and 
pDDIs. 
Drugs used in the treatment of cardiovascular and associated disorders such as 
amiodarone, diuretics, calcium channel blockers, digoxin, ACE inhibitors, oral 
anticoagulants, insulin or oral antidiabetics are often involved in ADRs observed in 
the elderly.5,10,12,67,87 These are the same drugs that are also often causing DDIs, 
potentially resulting in ADRs (table 3).88-90 Most of these ADRs observed in the 
elderly are dose-dependent reactions that may at least partially arise from age-
related physiological changes.18,87 Equally, most of the DDIs identified are 
pharmacodynamic interactions that result in a potentiation (or loss) of the 
pharmacological effect of the affected drug (table 3).89 Because of impaired 
homeostatic mechanisms, the elderly may be particularly sensitive to this kind of 
DDIs. 
A potentially serious pharmacodynamic DDI is the combination of ACE inhibitors with 
potassium sparing diuretics or potassium supplements, increasing the risk for 
hyperkalemia in predisposed elderly patients (see also age-related changes of the 
kidney).91 The combination of ACE inhibitors with 25 mg spironolactone has proven 
to reduce mortality in patients with severe congestive heart failure.92 However, more 
than 15% of the patients treated with spironolactone on top of an existing treatment 
for heart failure will develop clinically relevant hyperkalemia, especially patients with 
impaired renal function and poor monitoring.93,94 
Digoxin toxicity has also been reported as a frequent ADR leading to hospital 
admission.10,67,87 An important risk factor for digoxin toxicity is impairment of renal 
function, leading to reduced digoxin clearance and accumulation of the substance.95 
DDIs may also be responsible for the enhanced toxicity observed. Thiazide/loop 
diuretics may enhance the inhibition of Na-K-ATPase associated with digoxin 
secondary to diuretic induced hypokalemia and hypomagnesemia.91 Digoxin serum  
Table 3. Common drug-drug interactions (DDIs) and potential adverse drug reactions (ADRs) in the elderly88-91,96,97  
Drug or drug class Interacting drugs Mechanism Expected ADR due to DDI 
Digoxin Loop/thiazide diuretics Enhanced inhibition of Na-K-ATPase Digoxin toxicity 
 Pgp inhibitors e.g. clarithromycin, quinidine, 
verapamil, amiodarone 
Pgp inhibition Digoxin toxicity 
 Beta-adrenoceptor antagonists Additive effects Bradycardia, AV block 
ACE inhibitors Potassium sparing diuretics/potassium 
supplements 
Additive effects Hyperkalemia 
 NSAIDs Additive impairment of kidney 
function 
Hyperkalemia, renal failure 
Oral anticoagulants CYP inhibitors e.g. amiodarone, cimetidine, 
clarithromycin, cotrimoxazole, fluconazole, 
metronidazole  
Decreased metabolism Bleeding 
 CYP inducers e.g. barbiturates, 
carbamazepine, rifampicin, St. John’s wort 
Increased metabolism Thromboembolism due to reduced 
anticoagulant effect  
 Low dose acetylsalicylic acid, clopidogrel, 
NSAIDs 
Additive effects (platelet aggregation 
inhibition, gastric erosion for NSAIDs) 
Bleeding 
Beta-adrenoceptor antagonists Masking of hypoglycemic effect Severe hypoglycemia Insulin/oral antidiabetics 
(sulfonylureas, glinides) Other antidiabetics or insulin Additive effects Hypoglycemia 
 CYP 2C8/9 inhibitors e.g. cotrimoxazole, 
gemfibrozil, fluconazole 
Decreased metabolism Hypoglycemia 
Tricyclic antidepressants 
Antipsychoticsa 
Other anticholinergic drugs e.g. some 
antispasmodics, antiparkinson agents 
(biperiden, amantadine), first generation 
histamine H1 receptor antagonists 
Additive anticholinergic effects Xerostomia, blurred vision, urinary 
retention, tachycardia, confusion, 
cognitive impairment, delirium 
Sedative hypnotics Other sedative drugs e.g. first generation 
histamine H1 receptor antagonists, 
antipsychotics with high affinity to histamine 
H1 receptors (e.g. chlorpromazine, 
chlorprothixene, clozapine, quetiapine), 
maprotiline 
Additive sedative effects Excessive sedation, confusion, falls 
aAntipsychotics with high affinity to muscarinic receptors e.g. clozapine and phenothiazines. 
AV = atrioventricular; CYP = cytochrome P450; NSAIDs = nonsteroidal anti-inflammatory drugs; Pgp = P-glycoprotein. 
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concentrations may also indirectly be raised due to NSAID-induced renal failure.98 
Inhibitors of Pgp increase digoxin serum levels, because digoxin is a Pgp substrate.95 
The calcium channel blockers diltiazem and verapamil, and the antiarrhythmic agent 
amiodarone are often involved in pharmacokinetic pDDIs. Diltiazem and verapamil 
are inhibitors of CYP 3A4 and Pgp (verapamil > diltiazem).99-101 Amiodarone and its 
active metabolite desethylamiodarone are potent inhibitors of various CYP isozymes 
(CYP 1A1/2, 2A6, 2B6, 2C9, 2C19, 2D6, 3A4) as well as of Pgp, and may like 
diltiazem and verapamil enhance the risk for dose-dependent ADRs of CYP and Pgp 
substrates such as lipophilic statins.97,102,103 
The bleeding risk during treatment with oral anticoagulants seems to be increased in 
the elderly as suggested by a hazard ratio of 2.7 (95% confidence interval (CI)  
1.7-4.4) in patients older than 80 years compared to patients younger than 60 years, 
without major differences in achieved intensities of anticoagulant treatment.104 It has 
been hypothesized that comorbidities may play a role, because potential bleeding 
sites may be a consequence of other diseases or because actual bleeding may be 
worsened, e.g. by hypertension.104 In addition, the comedication and changes in the 
pharmacokinetics of coumarins may be reasons for higher bleeding rates in the 
elderly.104 Amiodarone is known to inhibit the metabolism of warfarin resulting in 
prolongation of the INR and increased risk of bleeding,105 if the warfarin dose is not 
adapted. The dosage of warfarin has to be reduced by 25-40%, depending on the 
amiodarone maintenance dose. The relative risk for a hemorrhagic gastrointestinal 
ulcer is increased by 12.7 (95% CI 6.3-25.7) in elderly patients using oral 
anticoagulants in combination with NSAIDs as compared to patients not using 
NSAIDs.106 Additive pharmacological effects and/or ADRs such as impairment of 
platelet aggregation, NSAID-induced gastric erosions or ulcers may primarily 
contribute to the increased risk of gastrointestinal hemorrhagic complications in 
NSAID users.106 
Hypoglycemia occurs more often in elderly patients treated with secretagogue 
antidiabetics such as sulfonylureas or glinides (nateglinide, repaglinide) as compared 
to non secretagogue oral antidiabetics, because glucose counterregulation seems to 
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be impaired with age.107 Hypoglycemia may also result from DDIs with other 
hypoglycemic agents or CYP inhibitors, especially inhibitors of CYP 2C8/9 (table 3).96 
 
Treatment with centrally acting drugs and associated risk for ADRs 
Beside cardiovascular drugs, elderly patients are also often treated with drugs 
affecting the CNS, namely benzodiazepines, antidepressants (including SSRIs), 
antipsychotics or analgesics.13 
Drug-induced cognitive impairment in the elderly has been associated with tricyclic 
antidepressants, other drugs with anticholinergic properties, pethidine and 
benzodiazepines.108,109 Additionally, these drugs may contribute to the manifestation 
of delirium in predisposed elderly patients, e.g. those with cognitive impairment.109,110 
The prevalence of delirium may be high in a hospital setting, ranging between  
14-24% at hospital admission, whereas the incidence of delirium arising during 
hospital stay may reach up to 56%.111 About two thirds of cases of delirium occur in 
patients with dementia.111 Patients treated with long-acting benzodiazepines at high 
doses are at higher risk for delirium as compared to those exposed with short-acting 
benzodiazepines at low doses.110 Delirium has also been associated with elevated 
serum anticholinergic activity that results often from additive anticholinergic effects of 
different drugs.112 In accordance, also antipsychotics with strong anticholinergic 
properties such as clozapine and phenothiazines have been reported to induce 
delirium.113 This is not the case for haloperidol and some atypical antipsychotics  
(e.g. risperidone, olanzapine, quetiapine), which are used for prophylaxis and 
treatment of delirium.56,111  Less serious peripheral manifestations of drugs with 
anticholinergic effects include dry mouth, tachycardia, blurred vision, urinary 
retention, and obstipation. Nevertheless, these ADRs may exacerbate underlying 
clinical conditions such as obstipation, xerostomia, glaucoma, and urinary retention 
that are common in elderly patients.114 Administration and especially combination of 
drugs with strong anticholinergic properties (e.g. antipsychotics such as clozapine or 
chlorpromazine, tricyclic antidepressants, first generation histamine H1 receptor 
antagonists) should therefore be avoided in the elderly.89  
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Another ADR of special concern in the elderly associated with the use of centrally 
acting drugs such as antidepressants, antipsychotics and benzodiazepines (long- 
and short-acting) is the increased risk of falls and fractures.115-119 Falls are a serious 
problem in the elderly and are associated with increased morbidity and mortality.120 
About 30-40% of community-dwelling adults aged ≥65 years fall each year, what may 
lead to serious injuries such as hip fractures or head trauma.120 Clinical conditions 
contributing to the increased risk of falls in the elderly are gait disturbance, muscle 
weakness, dizziness, vertigo, drop attacks, visual impairment, confusion, or postural 
hypotension.120 Use of centrally acting drugs such as tricyclic antidepressants, 
antipsychotics and benzodiazepines (with long and short half-life) may additionally 
increase the risk of falls and fractures.115-119 Some studies also report an association 
with SSRIs.115,116 However, the risks reported for the individual members of these 
drug classes markedly vary between different studies, probably due to the 
multifactorial etiology of falls.120 The combination of drugs with additive sedative 
effects should be avoided in the elderly, because the risk for falls and confusion may 
be further enhanced.89 
 
Potentially inappropriate medications increasing the risk for ADRs 
Some drugs may not be appropriate for the treatment of elderly patients, because the 
risk for ADRs outweighs the possible clinical benefit.121 The Beers criteria provide a 
list of drugs that should generally be avoided in patients aged ≥65 years or that 
should not be given to elderly patients with specific underlying diseases.121 The 
expected increase in ADRs in elderly patients treated with such drugs results from 
age-related, physiological changes, favoring the manifestation of dose-dependent 
reactions. Examples of drugs listed by Beers and commonly prescribed to elderly 
patients include nitrofurantoin (concern: renal adverse effects), long-acting 
benzodiazepines (concern: prolonged sedation, increased risk of falls and fractures), 
amitriptyline (concern: strong anticholinergic and sedation properties), doxazosin 
(concern: potential for hypotension, dry mouth, urinary problems), amiodarone 
(concern: prolongation of QT interval, torsade de pointes) and estrogens (concern: 
carcinogenic potential).122-124 
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Poor adherence following polymorbidity and polypharmacy 
Polymorbidity and polypharmacy are not only associated with an increased risk for 
ADRs and DDI-related ADRs, they may also lead to poor adherence and cause 
additional ADEs in the elderly. Some predisposing factors for poor adherence in 
elderly patients include type of disease, severity and duration of the illness, the 
number of comorbidities as well as the number of drugs prescribed.21 The presence 
of psychological problems, impairment of cognitive functions, vision and/or hearing, 
decrease of manual dexterity and occurrence of ADRs may significantly contribute to 
poor adherence.17,21 In addition, adherence for a specific drug is inversely 
proportional to the frequency of doses per day.17 Problems of adherence have 
especially been reported for the treatment of chronic cardiovascular diseases such 
as hypertension or heart failure, type 2 diabetes, hyperlipidemia, as well as for 
psychiatric disorders such as depression.17,125-128 
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Abstract 
Background and objective: Elderly patients may be at higher risk of DDIs due to 
polypharmacy. This study evaluated age-specific differences in the prevalence of 
clinically relevant pDDIs in ambulatory dyslipidemic patients treated with a statin. We 
hypothesized that elderly patients are at higher risk for pDDIs due to the presence of 
more drugs and drugs with a higher potential for DDIs. 
Methods: In this cross-sectional study, a total of 2’742 dyslipidemic ambulatory 
patients treated with a statin were included. Drug treatment was screened for 
clinically relevant pDDIs using an electronic drug interaction program (Drug Reax®). 
Results: There were 483 (17.6%) patients aged ≤54 years, 732 (26.7%) aged 55-64 
years, 924 (33.7%) aged 65-74 years, and 603 (22.0%) patients aged ≥75 years. 
Patients ≥75 years had significantly more pharmacologically active substances 
prescribed than patients aged ≤54 years (5.8 versus 3.8; p < 0.001). Cardiovascular 
diseases such as coronary heart disease, heart failure or arrhythmias were 
significantly more prevalent in patients aged ≥75 years than in younger patients. The 
overall prevalence of pDDIs increased significantly from 7.9% in those aged  
≤54 years to 18.4% in patients aged ≥75 years (p < 0.001). The frequency of both 
pDDIs associated with statins and non statin pDDIs increased with age. Risk factors 
for pDDIs in patients aged ≥75 years were arrhythmias, heart failure, and the number 
of pharmacologically active substances prescribed. The more frequent prescription of 
cardiovascular drugs with a high potential for pDDIs (e.g. amiodarone and digoxin) 
was mainly responsible for the observed increase in statin and non statin pDDIs. 
Conclusion: As compared to younger patients, elderly dyslipidemic patients are at a 
higher risk for clinically relevant pDDIs, mainly due to a higher number of drugs 
prescribed. In addition, patients aged ≥75 years were prescribed more drugs with a 
high potential for DDIs, especially drugs used for the treatment of arrhythmias and 
heart failure. The risk for adverse reactions following pDDIs may often be reduced by 
dose adjustment, close monitoring or selection of an alternative drug. 
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Introduction 
Concomitant administration of two or more drugs may lead to alterations of the 
therapeutic effect of one drug by another due to pharmacokinetic and/or 
pharmacodynamic interactions. The prevalence of pDDIs in patients with 
polypharmacy may be as high as 68%, depending on the patient setting and the 
definition of pDDIs.13,90,129,130 However, the fraction of pDDIs actually resulting in 
serious negative consequences for the affected patient, is relatively small.15,129,131 
The proportion of hospital admissions due to DDIs ranges between 0-3%.132 In 
geriatric inpatients, up to 15% of the patients hospitalized may experience mild to 
moderate ADRs due to DDIs.13 Known risk factors for pDDIs are the number of drugs 
prescribed and advanced age.89,129,133 Due to reduced homeostatic mechanisms and 
age-related pharmacodynamic and pharmacokinetic changes, elderly patients may 
be more sensitive to adverse effects resulting from DDIs.89 
Dyslipidemic patients treated with a statin are likely to receive several other drugs 
due to the presence of various comorbidities such as cardiovascular diseases or 
diabetes mellitus. Potential DDIs may therefore be quite common in this group of 
patients. The aim of our study was to explore age-related differences in diagnoses, 
associated prescription of drugs and pDDIs in ambulatory dyslipidemic patients 
treated with a statin. We hypothesized that pDDIs were more prevalent in the elderly 
not only because of exposure to a higher number of drugs, but also because of the 
prescription of drugs with a higher potential for DDIs. 
 
 
Methods 
Study population and data collection 
Between February and April 2002 practitioners from different parts of Switzerland 
participated in the cross-sectional Swiss Analysis Focused on the Evaluation of 
potential drug interactions (SAFE) trial. They collected data during five consecutive 
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days for all dyslipidemic patients treated with a statin which attended their practice. 
The study is described in detail elsewhere.16,91 For all patients, demographic data 
such as age, sex, actual diagnoses, the statin and comedication prescribed were 
recorded. Physicians were asked also to record over-the-counter (OTC) preparations 
taken by the patients. Diagnoses were coded according to the International Statistical 
Classification of Diseases version 10 (ICD-10) and drugs were coded according to 
the WHO Drug Dictionary (version 01-3, third quarter 2001). The medication profiles 
of all patients were screened for pDDIs using the online version of DrugReax®, an 
interactive database for drug interactions.134 
 
Classification of clinically relevant potential DDIs 
A pDDI involving a statin was considered clinically relevant if a) the prescribed statin 
was combined with a known inhibitor of its metabolism and/or transport, or b) at least 
one case report has been published describing a harmful reaction caused by the 
specific drug combination, and c) the combination could have had a potential serious 
outcome. A serious outcome was defined according to the International Conference 
on Harmonization (ICH) guidelines for clinical safety data management of ADRs135 as 
an event that may result in death, be life-threatening, require or prolong 
hospitalization and/or result in persistent or significant disability. Potential DDIs not 
involving a statin were considered to be clinically relevant if the expected outcome 
could have been serious (definition see above for statins). These included pDDIs of 
‘major severity’ according to the drug interaction program DrugReax® or, if not 
recognized by DrugReax®, according to other information sources such as standard 
literature,136,137 an additional online drug interaction database138 and/or Medline. In 
addition, each pDDI identified was checked by a pharmacist and a clinical 
pharmacologist if the criteria for clinical relevance were fulfilled. A pDDI was not 
considered clinically relevant, despite a rating of ‘major severity’ according to 
DrugReax®, if the interaction did not correspond to the actual clinical situation. For 
example, the interaction between ACE inhibitors and diuretics was not considered 
clinically relevant in patients under long-term treatment. The indicated risk of first-
dose hypotension (classification: ‘major severity’) does no longer exist in this case 
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and does therefore not reflect the actual clinical situation. Also topical treatment with 
ketoconazole in a patient treated with a CYP 3A4 substrate was not considered to be 
clinically relevant. 
 
Statistical analysis 
Patients were classified into four different age groups, i.e. ≤54 years, 55-64 years, 
65-74 years and ≥75 years. Potential differences of numerical variables between age 
groups were analyzed with one-way ANOVA, or with Pearson’s chi-square test for 
categorical variables. Because of multiple testing, the significance level was adjusted 
according to Bonferroni-Holm.139 Significance was assessed for the corrected 5%, 
1% and 0.1% significance levels. The exact method was used to calculate 95% CI for 
proportions.140 Differences in the number of specific pDDIs between age groups were 
not analyzed statistically, because of the limited number of pDDIs identified. 
Logistic regression analyses using a backward elimination procedure with Wald 
statistics and likelihood-ratio statistics were performed to identify risk factors for the 
occurrence of clinically relevant pDDIs separately for each of the 4 different age 
groups. As explanatory dichotomous variables sex, German-, French- or Italian-
speaking part of Switzerland, professional specialty of the practitioner (internist, 
cardiologist or other), diagnosis of hypertension, diabetes mellitus, coronary heart 
disease, heart failure, arrhythmias, depression/psychiatric disorders, cerebrovascular 
diseases, rheumatic diseases, disorders of the musculoskeletal system, 
gout/hyperuricemia, epilepsy or other diagnoses, and use of pravastatin were 
included in the model. Continuous numerical variables included in the model were 
age, number of diagnoses, number of pharmaceutical preparations and number of 
pharmacologically active substances prescribed. Explanatory variables with a p-value 
<0.1 were included in the final model. Relative risk estimates are expressed as odds 
ratios (OR) with 95% CI. 
Statistical analyses were performed with SPSS for Windows version 13.0 (SPSS Inc., 
Chicago, USA). 
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Results 
Of the 2'753 patients initially registered in this cross-sectional study, 11 patients were 
excluded (10 patients were not receiving a statin, 1 patient was prescribed 
cerivastatin, which was withdrawn from the market in 2000). The mean age (± SD) of 
the study population (n = 2’742; 61.6% male) was 65.1 ± 11.2 years. There were 483 
(17.6%) patients aged ≤54 years, 732 (26.7%) patients aged 55-64 years, 924 
(33.7%) patients aged 65-74 years and 603 (22.0%) patients aged ≥75 years. Patient 
characteristics are presented in table 4. The proportion of female patients increased 
significantly from 27.1% in the ≤54 years-old to 46.3% in the group of patients  
≥75 years (p < 0.001). On average, patients ≥75 years of age had significantly more 
diagnoses (3.5 versus 2.8; p < 0.001) and more pharmacologically active substances 
prescribed (5.8 versus 3.8; p < 0.001) than patients aged ≤54 years. However, the 
number of active compounds prescribed to older patients is not only a function of the 
number of diagnoses, since the average number of substances per diagnosis 
increased with higher age (1.52 ± 0.90 in the group of patients aged ≤54 years 
versus 1.88 ± 1.10 in the group of patients aged ≥75 years; p < 0.001). Hypertension, 
coronary heart disease and diabetes mellitus were the three most prevalent 
comorbidities in the whole study population with overall prevalences of 52.1%, 42.5% 
and 19.0%, respectively. There was a significant increase in the prevalence of 
hypertension, coronary heart disease, heart failure, arrhythmias and cerebrovascular 
diseases with increasing age, whereas the prevalence of depression and/or 
psychiatric disorders was significantly decreased in older as compared to younger 
patients.  
Cardiovascular drugs were most often prescribed concomitantly with a statin (see 
table 5). The prescription frequency for low dose acetylsalicylic acid, beta-
adrenoceptor antagonists, thiazides and/or loop diuretics, ACE inhibitors, calcium 
channel blockers (dihydropyridines, verapamil, diltiazem), oral anticoagulants 
(phenprocoumon and acenocoumarol; warfarin is not marketed in Switzerland), 
potassium-sparing diuretics, amiodarone, and digoxin increased significantly with 
advancing age. Only the prescription of antidepressants was significantly lower in 
patients aged ≥75 years compared to patients aged ≤54 years (p < 0.01), reflecting 
 Table 4. Patient characteristics and comorbidities of 2'742 patients with dyslipidemia stratified by age groups 
Age groups (years) 
Characteristics 
Total 
(n = 2'742) 
≤54 
(n = 483) 
55-64 
(n = 732) 
65-74 
(n = 924) 
≥75 
(n = 603) p-value 
Female, n (%) 1'052 (38.4) 131 (27.1) 251 (34.3) 391 (42.3) 279 (46.3) <0.001 
Number of diagnoses, mean ± SD 3.3 ± 1.55 2.8 ±1.42 3.1 ± 1.54 3.4 ± 1.54 3.5 ± 1.56 <0.001 
Number of active substances prescribed including statins, mean ± SD 4.9 ± 2.37 3.8 ± 2.15 4.5 ± 2.22 5.2 ± 2.36 5.8 ± 2.34 <0.001 
Number of active substances per diagnosis, mean ± SD 1.71 ± 0.98 1.52 ± 0.90 1.70 ± 1.00 1.70 ± 0.93 1.88 ± 1.10 <0.001 
Hypertension, n (%) 1'428 (52.1) 187 (38.7) 363 (49.6) 537 (58.1) 341 (56.6) <0.001 
Diabetes mellitus, n (%) 520 (19.0) 74 (15.3) 132 (18.0) 211 (22.8) 103 (17.1) <0.01 
Coronary heart disease, n (%) 1'166 (42.5) 137 (28.4) 271 (37.0) 428 (46.3) 330 (54.7) <0.001 
Heart failure, n (%) 130 (4.7) 15 (3.1) 21 (2.9) 42 (4.5) 52 (8.6) <0.001 
Arrhythmia, n (%) 188 (6.9) 6 (1.2) 40 (5.5) 68 (7.4) 74 (12.3) <0.001 
Cerebrovascular disease, n (%) 461 (16.8) 38 (7.9) 85 (11.6) 184 (19.9) 154 (25.5) <0.001 
Depression/psychiatric disorder, n (%) 423 (15.4) 119 (24.6) 140 (19.1) 102 (11.0) 62 (10.3) <0.001 
Rheumatic disease/disorder of musculoskeletal system, n (%) 416 (15.2) 52 (12.5) 110 (26.4) 149 (35.8) 105 (25.2) NS 
Gout/hyperuricemia, n (%) 103 (3.8) 13 (2.7) 24 (3.3) 44 (4.8) 22 (3.6) NS 
Epilepsy, n (%) 16 (0.6) 7 (1.4) 4 (0.5) 4 (0.4) 1 (0.2) NS 
Other diagnoses, n (%) 244 (8.9) 93 (19.3) 75 (10.2) 59 (6.4) 17 (2.8) <0.001 
NS = not significant; SD = standard deviation. 
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the observed decrease in the prevalence of depression and other psychiatric 
disorders with increasing age. With increasing number of pharmacologically active 
substances prescribed per patient, also the prevalence of patients with clinically 
relevant pDDIs increased. In patients aged ≤54 years, the prevalence of pDDIs 
increased from 3.4% (95% CI 1.3-7.2%) when 2-3 active substances were prescribed 
to 22.7% (95% CI 11.5-37.8%) in patients receiving ≥7 substances concomitantly 
(figure 4). This increase was even more pronounced in patients aged ≥75 years, 
reaching 33.8% (95% CI 27.4-40.7%) when ≥7 substances were prescribed. 
 
Logistic regression analysis identified male sex (OR 2.9; 95% CI 1.1-7.5), number of 
pharmaceutical preparations prescribed (OR 1.8; 95% CI 1.5-2.2) and psychiatric 
disorders (OR 2.4; 95% CI 1.1-5.3) as risk factors for clinically relevant pDDIs in 
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Figure 4. Number of pharmacologically active substances prescribed and prevalence of potential drug-drug 
interactions (pDDIs) stratified by age group. The figure shows the proportion (± 95% confidence interval) of 
patients with a pDDI stratified by age and number of active substances prescribed. While the proportion of 
patients with a pDDI increases with the number of active substances prescribed, there is no significant 
increase with age. A total of 704 patients were prescribed 2-3 active substances (range: 92-221 patients in 
the different age groups), 519 patients 4 substances (range: 87-169 patients), 807 patients 5-6 substances 
(range: 113-298 patients), and 590 patients were prescribed ≥7 active substances concomitantly (range:  
44-226 patients). 
 Table 5. Prevalence of the most frequently prescribed comedications in 2‘742 dyslipidemic patients stratified by age groups 
 
Age groups (years)  
Substances or therapeutic groups 
Total 
(n = 2'742) 
n (%) 
≤54 
(n = 483) 
n (%) 
55-64 
(n = 732) 
n (%) 
65-74 
(n = 924) 
n (%) 
≥75 
(n = 603) 
n (%) p-value 
Acetylsalicylic acid (low dose) 1‘258 (45.9) 173 (35.8) 323 (44.1) 439 (47.5) 323 (53.6) <0.001 
Beta-adrenoceptor antagonists 1‘145 (41.8) 169 (35.0) 291 (39.8) 408 (44.2) 277 (45.9) <0.01 
Thiazide or loop diuretics 900 (32.8) 82 (17.0) 195 (26.6) 333 (36.0) 290 (48.1) <0.001 
ACE inhibitors 778 (28.4) 91 (18.8) 183 (25.0) 288 (31.2) 216 (35.8) <0.001 
Angiotensin II receptor antagonists 551 (20.1) 83 (17.2) 156 (21.3) 193 (20.9) 119 (19.7) NS 
Oral antidiabetics 533 (19.4) 73 (15.1) 142 (19.4) 231 (25.0) 87 (14.4) NT 
Benzodiazepines 499 (18.2) 79 (16.4) 112 (15.3) 175 (18.9) 133 (22.1) NS 
Nonsteroidal anti-inflammatory drugs 427 (15.6) 85 (17.6) 128 (17.5) 132 (14.3) 82 (13.6) NS 
Calcium channel blockers (dihydropyridines) 403 (14.7) 29 (6.0) 90 (12.3) 171 (18.5) 113 (18.7) <0.001 
Antidepressants (incl. St John’s wort) 363 (13.2) 80 (16.6) 115 (15.7) 96 (10.4) 72 (11.9) <0.01 
Oral anticoagulants (phenprocoumon, acenocoumarol)a 320 (11.7) 19 (3.9) 52 (7.1) 135 (14.6) 114 (18.9) <0.001 
Potassium-sparing diuretics 161 (5.9) 11 (2.3) 34 (4.7) 59 (6.4) 57 (9.5) <0.001 
Clopidogrel 136 (5.0) 17 (3.5) 36 (4.9) 46 (5.0) 37 (6.1) NS 
Insulin 133 (4.9) 16 (3.3) 31 (4.2) 51 (5.5) 35 (5.8) NT 
Allopurinol 122 (4.5) 12 (2.5) 28 (3.8) 51 (5.5) 31 (5.1) NT 
Calcium channel blockers (verapamil or diltiazem) 100 (3.7) 2 (0.4) 25 (3.4) 47 (5.1) 26 (4.3) <0.01 
Antipsychotics 98 (3.6) 22 (4.6) 29 (4.0) 31 (3.4) 16 (2.7) NT 
Amiodarone 82 (3.0) 2 (0.4) 15 (2.1) 36 (3.9) 29 (4.8) <0.001 
Digoxin 67 (2.4) 0 8 (1.1) 27 (2.9) 32 (5.3) <0.001 
Antiepileptics 56 (2.0) 16 (3.3) 12 (1.6) 16 (1.7) 12 (2.0) NT 
Tramadol 24 (0.9) 4 (0.8) 10 (1.4) 5 (0.5) 5 (0.8) NT 
Other lipid lowering drugs: fibrates and nicotinic acid 20 (0.7) 5 (1.0) 6 (0.8) 8 (0.9) 1 (0.2) NT 
Ginkgo 18 (0.7) 1 (0.2) 1 (0.1) 7 (0.8) 9 (1.5) NT 
Potassium 16 (0.6) 1 (0.2) 4 (0.6) 7 (0.8) 4 (0.7) NT 
aOnly the oral anticoagulants phenprocoumon and acenocoumarol are marketed in Switzerland (but not warfarin). 
NS = not significant; NT = not tested to avoid multiple testing on the same sample. 
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patients ≤54 years (see table 6). In ≥55 years-old patients, in addition to the number 
of pharmaceutical preparations or pharmacologically active substances prescribed a 
diagnosis of arrhythmia or heart failure was associated with a higher risk for pDDIs 
(table 6). In each model, either the number of pharmaceutical preparations or 
pharmacologically active substances resulted to be a significant risk factor, 
demonstrating the collinearity between these two variables. 
 
Table 7 lists the most prevalent of the 591 clinically relevant pDDIs found in  
401 patients (14.6% of all patients studied) stratified by age. The prevalence of total 
pDDIs increased significantly (p < 0.001) from 7.9% in the group of patients aged  
≤54 years to 18.4% in those aged ≥75 years (figure 5). Accordingly, taking into 
account only patients with pDDIs, the mean number of pDDI per patient increased 
from 1.21 ± 0.84 in the group of patients aged ≤54 years to 1.56 ± 0.99 in the group 
of patients aged ≥75 years. While almost all of the 198 pDDIs involving statins were 
pharmacokinetic interactions, in 65% of the 393 non statin pDDIs, the underlying 
Table 6. Factors significantly associated with an increased risk of clinically relevant potential drug-drug 
interactions using age-specific multivariate logistic regression analysis 
 Age groups 
Risk factors 
≤54 years 
(n = 483) 
OR [95% CI] 
55-64 years 
(n = 732) 
OR [95% CI] 
65-74 years 
(n = 924) 
OR [95% CI] 
≥75 years 
(n = 603) 
OR [95% CI] 
Male sex 2.9 [1.1-7.5] NS NS NS 
Number of preparations or 
active substancesa 
1.8 [1.5-2.2] 1.7 [1.5-1.9] 1.5 [1.4-1.6] 2.4 [1.5-3.9] 
Psychiatric disorders 2.4 [1.1-5.3] NS NS -b 
Arrhythmia NS 9.1 [4.2-19.6] 4.7 [2.6-8.4] 5.6 [3.1-10.1] 
Heart failure NS 3.8 [1.3-10.7] 3.6 [1.8-7.4] 2.7 [1.3-5.4] 
aIn each model either the number of pharmaceutical preparations or pharmacologically active substances 
resulted as a significant risk factor due to collinearity problems using multivariate logistic regression analysis. 
bOdds ratio for psychiatric disorders indicated a significantly reduced risk (OR 0.3 [95% CI 0.1-0.8]; p < 0.05) 
in patients aged ≥75 years. 
NS = not significant; OR = odds ratio. 
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mechanism was pharmacodynamic. The prevalence of both statin and non statin 
pDDIs increased with age, whereas the proportion of statin interactions in relation to 
the total number of pDDIs decreased from 41.3% in patients aged ≤54 years to 
30.6% in patients aged ≥75 years. Overall, the most common pDDI involving a statin 
was the combination of amiodarone with atorvastatin or simvastatin, increasing the 
risk for rhabdomyolysis.103 Compared to younger patients, those aged ≥75 years 
were more likely to be exposed to this potentially harmful drug combination. Also the 
pDDI between atorvastatin or simvastatin and digoxin, which is associated with 
increased digoxin serum concentrations and potential digoxin toxicity, was more 
frequent in the elderly. On the other hand, the prevalence of the pharmacokinetic 
interaction between fluoxetine in combination with atorvastatin, fluvastatin, or 
simvastatin decreased with age. The only pharmacodynamic pDDI involving statins 
was the combination with other lipid-lowering drugs, in particular with nicotinic acid. 
Non statin interactions commonly implicated cardiovascular drugs such as ACE 
 
Figure 5. Prevalence of potential drug-drug interactions (pDDIs) stratified by age groups. Also the proportion 
of patients with statin and non statin pDDIs, respectively both of them, contributing to the total amount of 
clinically relevant pDDIs is indicated. * indicates a significant difference in the prevalence of total pDDIs 
between the age groups. 
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inhibitors, amiodarone, beta-adrenoceptor antagonists, digoxin or oral 
anticoagulants, which were more often prescribed to elderly patients. 
 
 
Discussion 
Dyslipidemic patients treated with a statin were selected as a study population, 
because treatment with statins can be associated with potentially serious adverse 
reactions such as rhabdomyolysis that are frequently associated with underlying 
DDIs.141 Statins are commonly used as a long-term treatment and elderly patients 
are at special risk for pDDIs because of polymorbidity and consequent prescription of 
multiple drugs.141,142 In addition, patients with dyslipidemia have a high risk for 
cardiovascular diseases143 and the prevalence of cardiovascular disorders is known 
to increase with age.50 Drugs used for the treatment of cardiovascular disorders are 
frequently involved in pDDIs, especially in elderly patients.89 
Our study shows that the prevalence of clinically relevant pDDIs significantly 
increased with advancing age. This is consistent with the findings in the 
literature.89,133,144 Only 7.9% of the patients aged ≤54 years have been identified with 
serious pDDIs, whereas the prevalence reached 18.4% in patients aged ≥75 years. 
Importantly, the frequency of both statin and non statin pDDIs increased with age.  
Using logistic regression analysis, the number of pharmaceutical preparations or 
pharmacologically active substances prescribed were identified as risk factors for 
pDDIs, independently of the patient’s age. Polypharmacy is a well known risk factor 
for pDDIs.89,129,144 The higher number of comorbidities and pharmacologically active 
substances per diagnosis prescribed may partly explain the higher prevalence of 
pDDIs observed in patients aged ≥75 years compared to younger patients. An 
additional explanation for the observed increase in the prevalence of pDDIs with 
advancing age may be the prescription of drugs with a higher potential for DDIs. 
Especially drugs used for the treatment of heart failure and/or arrhythmias were often 
involved in clinically relevant pDDIs. These drugs have previously been described to 
be commonly responsible for pDDIs in the elderly.89,130
Table 7. List of the most prevalent clinically relevant potential drug-drug interactions (pDDIs) identified in statin-treated patients with dyslipidemia stratified by age group. When 
applicable, the second listed drug or drug class is the one affected by the pDDI. 
Number of pDDIs, n (%) 
Interacting drugs Mechanism All patients ≤54 years 55-64 years 65-74 years ≥75 years 
Total number of pDDIs  591 (100.0) 46 (100.0) 140 (100.0) 232 (100.0) 173 (100.0) 
Interactions involving a statin (total)  198 (33.5) 19 (41.3) 47 (33.6) 79 (34.1) 53 (30.6) 
Amiodarone – atorvastatin or simvastatin k 52 (8.8) 1 (2.2) 10 (7.1) 22 (9.5) 19 (11.0) 
Diltiazem/verapamil – atorvastatin or simvastatin k 45 (7.6) - 10 (7.1) 25 (10.8) 10 (5.8) 
Atorvastatin/simvastatin – digoxin k 43 (7.3) - 4 (2.9) 18 (7.8) 21 (12.1) 
Fluoxetine/norfluoxetine – atorvastatin, fluvastatin or simvastatin k 29 (4.9) 10 (21.7) 15 (10.8) 3 (1.3) 1 (0.6) 
Other lipid-lowering drugsa – all statins k/d 18 (3.0) 5 (10.9) 5 (3.6) 7 (3.0) 1 (0.6) 
Other pDDIs involving a statin  11 (1.9) 3 (6.5) 3 (2.1) 4 (1.7) 1 (0.6) 
Interactions not involving a statin (total)  393 (66.5) 27 (58.7) 93 (66.4) 153 (65.9) 120 (69.4) 
ACE inhibitor – potassium sparing diuretic or potassium d 57 (9.6) 5 (10.9) 17 (12.1) 21 (9.0) 14 (8.1) 
Loop/thiazide diuretic – digoxin d 42 (7.1) - 5 (3.6) 15 (6.5) 22 (12.7) 
ACE inhibitor – allopurinol u 40 (6.8) 2 (4.3) 9 (6.4) 18 (7.8) 11 (6.4) 
Amiodarone – oral anticoagulantb k 33 (5.6) 1 (2.2) 6 (4.3) 17 (7.3) 9 (5.2) 
Amiodarone – beta-adrenoceptor antagonist d 31 (5.3) - 7 (5.0) 14 (6.0) 10 (5.8) 
ASS – oral anticoagulantb or heparin d 29 (4.9) 7 (15.3) 6 (4.3) 10 (4.3) 6 (3.5) 
Beta-adrenoceptor antagonist – antidiabetic agents d 22 (3.7) 2 (4.3) 4 (2.9) 9 (3.9) 7 (4.0) 
Beta-adrenoceptor antagonist – digoxin d/(k) 21 (3.6) - 3 (2.1) 6 (2.6) 12 (7.0) 
Diltiazem/verapamil – beta-adrenoceptor antagonist d/(k) 18 (3.0) - 6 (4.3) 8 (3.4) 4 (2.3) 
Ginkgo – oral anticoagulantb or ASS d 16 (2.7) - 1 (0.7) 6 (2.6) 9 (5.2) 
NSAID – ASS d 13 (2.2) 2 (4.3) 5 (3.6) 3 (1.3) 3 (1.7) 
Other non statin interactions  71 (12.0) 8 (17.4) 24 (17.1) 26 (11.2) 13 (7.5) 
aOther lipid-lowering drugs: fibrates, nicotinic acid. 
bOral anticoagulants available in Switzerland are phenprocoumon and acenocoumarol; the pDDIs identified for these substances are also relevant for warfarin. 
ASS = Acetylsalicylic acid (low dose); d = pharmacodynamic interaction; k = pharmacokinetic interaction; NSAID = nonsteroidal anti-inflammatory drug; SD = standard 
deviation; u = mechanism of interaction is unknown. 
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these drugs the diagnoses heart failure and arrhythmia have been identified as risk 
factors for pDDIs in patients aged ≥55 years in our study. The increase in the 
proportion of interactions involving cardiovascular drugs related to the total number of 
pDDIs with age supports the importance of the potential risk associated with this drug 
class. 
The most frequent non statin pDDI of major severity in all age groups in our study 
was the combination of ACE inhibitors with potassium-sparing diuretics, which 
increases the risk for hyperkalemia. The combination of ACE inhibitors with 25 mg 
spironolactone has proven to reduce the mortality in patients with severe congestive 
heart failure.92 However, in 13% of the patients, the addition of spironolactone to an 
existing treatment with ACE inhibitors may lead to hyperkalemia.93 Other risk factors 
identified are age, renal impairment, diabetes mellitus type 2 and spironolactone 
doses >25 mg daily.145 Close monitoring of renal function and serum potassium 
concentrations may help to prevent the development of hyperkalemia. 
In our study, the frequency of digoxin prescription and the prevalence of pDDIs 
involving digoxin increased with advancing age (table 7). Because of its 
pharmacological properties and narrow therapeutic range, digoxin is a drug 
frequently implicated in serious pharmacodynamic and/or pharmacokinetic pDDIs.89 
In the elderly, digoxin toxicity may be further enhanced due to an age-related decline 
in renal function and subsequent decrease in digoxin clearance, but also due to an 
enhanced susceptibility to digoxin, even at therapeutic concentrations.95,146,147 
Potential DDIs identified more often in elderly patients treated with digoxin included 
the combination with loop/thiazide diuretics, beta-adrenoceptor antagonists, 
atorvastatin or simvastatin. By inducing hypokalemia or hypomagnesemia, loop and 
thiazide diuretics may enhance the inhibitory effect of cardiac glycosides on  
Na-K-ATPase through indirect pharmacodynamic mechanisms.148 Concomitant use 
of beta-adrenoceptor antagonists and digoxin may be associated with the risk of 
bradycardia due to additive pharmacological effects.134 Pharmacokinetic pDDIs 
associated with digoxin toxicity include inhibition of Pgp-mediated transport of 
digoxin, possibly leading to increased intestinal digoxin absorption and decreased 
renal and biliary excretion, leading to increased serum concentrations. Recently, it 
has been shown in vitro that carvedilol, propranolol and bisoprolol may inhibit the 
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activity of Pgp.149 In human pharmacokinetic studies, carvedilol, the most efficient 
Pgp inhibitor of the beta-adrenoceptor antagonists tested, has shown to increase 
bioavailability of digoxin, but the clinical relevance has to be determined.150,151 In 
analogy, concomitant administration of simvastatin, lovastatin and atorvastatin may 
increase digoxin serum concentrations up to 20%, because of the inhibition of  
Pgp-mediated transport.141,152 On the other hand, pravastatin did not show alterations 
in the pharmacokinetics of digoxin,152,153 and the effect of fluvastatin seems not to be 
clinically relevant.154 Therapeutic drug monitoring may help to prevent toxic effects 
associated with higher digoxin concentrations. 
Drugs used in the treatment of arrhythmias were also often involved in pDDIs. The 
most common pDDIs with antiarrhythmics identified in our study were the 
pharmacokinetic interactions involving amiodarone, diltiazem or verapamil in 
combination with atorvastatin or simvastatin. Amiodarone, diltiazem and verapamil 
are inhibitors of different hepatic CYP isozymes, in particular CYP 3A4.100-102  
CYP 3A4 is primarily responsible for the metabolism of simvastatin, atorvastatin and 
lovastatin. Since the occurrence of myotoxicity associated with statins is considered 
to be dose-dependent,142,155-157 pDDIs of CYP 3A4 inhibitors with simvastatin, 
atorvastatin or lovastatin are associated with an increased risk for rhabdomyolysis.158 
In addition, older patients, particularly thin or frail women, or those with multisystem 
diseases, in particular patients with renal failure, seem to be at higher risk for statin-
associated myopathy and should therefore be monitored carefully for early signs of 
muscle discomfort or weakness.142,155  
In our study, the prevalence of depression and psychiatric disorders was highest in 
patients aged ≤54 years and was identified as a risk factor for pDDIs in this age 
group. Several reasons may contribute to this observation, which may not accurately 
reflect the age-dependent prevalence of depression.159 Considering the low 
prevalence of psychiatric disorders compared with the amount of centrally acting 
drugs prescribed, it can be assumed that the physicians did not report all psychiatric 
disorders in elderly patients. In addition, depression is often underdiagnosed and 
undertreated in the elderly, because somatic symptoms may predominate or 
dementia and/or comorbid medical illnesses may complicate the recognition of 
depressive symptoms.160,161 Patients aged ≤54 years had a higher prevalence of 
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pDDIs between fluoxetine and atorvastatin, fluvastatin or simvastatin than elderly 
patients. Fluoxetine and its active metabolite norfluoxetine may increase the risk for 
rhabdomyolysis through inhibitory effects on the metabolism of these statins. The 
lower prescription rate of fluoxetine in the elderly probably reflects the awareness of 
the physicians that this drug should better be avoided in this patient group, because 
of the long half-life of the drug and of its active metabolite, increasing the risk for 
dose-dependent ADRs.121 
The identification of male sex as a risk factor for pDDIs in patients aged ≤54 years 
may be related to the earlier onset of cardiovascular disorders requiring drug 
treatment in men as compared to women.143 
While this study demonstrates the frequency and the type of pDDIs in different age 
groups, it has also several limitations. According to the inclusion criteria, all patients 
studied had dyslipidemia and were treated with a statin. Since dyslipidemia is often 
associated with the metabolic syndrome, most patients had more than one diagnosis 
and were treated with multiple drugs, possibly decreasing the difference in the 
frequency of pDDIs between younger and older patients. In addition, since pDDIs of 
lower severity were excluded, the significance of pDDIs may have been 
underestimated. Adherence to the prescribed medication, which may influence the 
clinical impact of an identified pDDI, has not been assessed in the current study. The 
study was not designed to evaluate adverse outcomes resulting from pDDIs, 
decreasing the clinical relevance of our results. Furthermore, the use of a drug 
interaction program is helpful to identify pDDIs, but it has also limitations. It is for 
example not possible to control for factors influencing the relevance of a pDDI, e.g. 
dosage, time of administration, beginning and duration of treatment, and underlying 
diseases.16,144 
 
 
Conclusion 
Our study demonstrates that elderly dyslipidemic patients treated with a statin are at 
a higher risk for clinically relevant pDDIs than younger ones, irrespective whether a 
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statin is involved in the pDDI or not. The principle reason for this finding is the 
prescription of a higher number of drugs in the elderly, due to an increased number 
of diagnoses and due to the prescription of more drugs per diagnosis. Cardiac 
arrhythmias and heart failure are two diagnoses with a higher prevalence in the 
elderly and both are risk factors for pDDIs in this patient group. Beside the higher 
number of active substances prescribed, the prescription of cardiovascular drugs with 
a high potential for DDIs, e.g. digoxin or amiodarone, may also contribute to the 
observed higher prevalence of pDDIs with age. The combination of amiodarone with 
atorvastatin or simvastatin was the most frequent statin interaction in patients aged 
≥75 years. 
Elderly patients may be more prone to ADRs resulting from pDDIs, due to impaired 
homeostatic mechanisms and age-related pharmacodynamic and pharmacokinetic 
changes. In order to avoid the occurrence of ADRs associated with DDIs, the number 
of drugs prescribed should be minimized as much as possible. Drugs with a high 
potential for pDDIs must be recognized as such in order to take appropriate 
measures to minimize the risk for pDDIs such as choosing an alternative treatment 
with a lower risk for pDDIs, adjusting the dosage or close monitoring of therapy. 
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Abstract 
Background and objective: Inappropriate drug use is one of the risk factors for 
ADRs in the elderly. We hypothesized that, in elderly patients, geriatricians are more 
aware of PIMs and may replace or stop PIMs more frequently as compared with 
internists. We therefore evaluated and compared the prevalence of PIMs as well as 
anticholinergic drug use throughout hospital stay in elderly patients admitted to a 
medical or geriatric ward. 
Methods: In this retrospective cross-sectional study, 800 patients aged ≥65 years 
admitted to a general medical or geriatric ward of a 700-bed teaching hospital in 
Switzerland during 2004 were included. PIMs were identified using the Beers criteria 
published in 2003. The prevalence of anticholinergic drug use was assessed based 
on drug lists published in the literature. 
Results: The prevalence of use of PIMs that should generally be avoided was similar 
in medical and geriatric inpatients both at admission (16.0% versus 20.8%, 
respectively; p = 0.08) and at discharge (13.3% versus 15.9%, respectively;  
p = 0.31). In contrast to medical patients, the reduction in the prevalence of use of 
PIMs between admission and discharge in geriatric patients reached statistical 
significance (p < 0.05). Overall, the three most prevalent inappropriate drugs/drug 
classes were amiodarone, long-acting benzodiazepines and anticholinergic 
antispasmodics. At admission the prevalence of use of PIMs related to a specific 
diagnosis was not significantly different between patients hospitalized to a medical or 
a geriatric ward (14.0% versus 17.5%, respectively; p = 0.17), as compared with the 
significant difference evident at hospital discharge (11.7% versus 23.7%, 
respectively; p < 0.001). This was largely because of a higher prescription rate of 
platelet aggregation inhibitors in combination with low-molecular-weight heparins 
(LMWHs) and benzodiazepines in patients with a history of falls and syncope. The 
proportions of patients taking anticholinergic drugs in medical and geriatric patients at 
admission (13.0% versus 17.5%, respectively; p = 0.08) and discharge  
(12.2% versus 16.5%, respectively; p = 0.10) were similar. 
Conclusion: Inappropriate drug use as defined by the Beers criteria was common in 
both medical and geriatric inpatients. Compared with internists, geriatricians appear 
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to be more aware of PIMs that should generally be avoided, but less aware of PIMs 
related to a specific diagnosis, and of the need to avoid anticholinergic drug use. 
However, the results of this study should be interpreted with caution because some 
of the drugs identified as potentially inappropriate may in fact be beneficial when the 
patient’s clinical condition is taken into consideration. 
 
 
Introduction 
Because of age-related polymorbidity, drug regimen for elderly patients regularly 
consist of more than one drug. In addition to polypharmacy and related problems 
such as increased risk of DDIs and ADRs, various other factors (including age-
related changes in pharmacokinetics and pharmacodynamics or underlying diseases) 
must be considered when prescribing drugs to elderly patients. Inappropriate drug 
use is one important aspect of suboptimal prescribing in the elderly.162 
A drug prescription is defined as potentially inappropriate when the potential risk for 
ADRs outweighs the possible clinical benefit.121 The Beers criteria provide a list of 
potentially inappropriate drugs or drug classes that should generally be avoided in 
the treatment of patients aged ≥65 years or when a specific underlying disease is 
present.121 It has been estimated that in elderly patients, approximately 12% of 
hospital admissions are caused by ADRs.10,11 In some studies, use of PIMs 
according to the Beers criteria was identified as a risk factor for ADRs.10,163,164 
Avoiding PIMs and using safer alternatives instead could therefore contribute to 
improved drug safety in the elderly. 
Drugs with anticholinergic properties pose a special risk to elderly patients. The 
elderly are more susceptible to anticholinergic effects because acetylcholine levels 
decrease with advanced age and are typically reduced in patients with Alzheimer’s 
disease and other dementias.112 In particular, combining two or more drugs with 
anticholinergic properties may enhance the risk of peripheral anticholinergic effects 
such as dry mouth, blurred vision or increased heart rate. Anticholinergic load can 
also often induce severe central nervous ADRs, ranging from sedation and confusion 
Study II: Potentially inappropriate medication use in the elderly 
53 
to delirium and cognitive impairment,108,112,165 which, in the elderly, may often go 
unrecognized as such. 
Recently, Laroche et al.166 showed that hospitalization on geriatric wards can result in 
a decrease in prescription of PIMs as well as anticholinergic drugs. Potentially 
inappropriate drugs were identified using the Beers criteria published in 1997 and 
medications with anticholinergic properties other than those listed in the Beers 
criteria were added. However, these investigators did not evaluate drugs that should 
not be used in the presence of specific underlying diseases. Similarly, Saltvedt et 
al.167 also showed that hospitalization in a geriatric ward improved the 
appropriateness of drug treatment in elderly patients. Compared with patients on a 
medical ward, patients on a geriatric ward were prescribed fewer drugs with 
anticholinergic properties and experienced fewer pDDIs. 
The aim of this retrospective cross-sectional study was to assess and compare the 
prevalence of use of PIMs, taking into account underlying diseases, and the 
exposure prevalence of anticholinergic drug use in medical and geriatric patients 
aged ≥65 years throughout hospital stay. It was hypothesized that geriatricians are 
more aware of PIMs and would therefore replace or stop PIMs more frequently than 
internists. 
 
 
Methods 
Study population and data collection 
Eight hundred patients aged ≥65 years consecutively admitted either to a general 
medical or a geriatric ward of the University Hospital of Basel, Basel, Switzerland, in 
the year 2004 were retrospectively identified. This hospital is a 700-bed teaching 
institution providing primary and tertiary care to an urban population of approximately 
200'000 inhabitants. The main emphasis of the 45-bed general medical ward 
selected for the study is treatment of patients with gastroenterological, hematological, 
infectious, nephrological, oncological, and/or rheumatological diseases. The 28-bed 
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geriatric ward specializes in the treatment of patients with complex geriatric diseases, 
with particular emphasis on decubitus ulcers, senile delirium, dementia and 
malnutrition. Patients were excluded if they were discharged on the same day they 
were admitted or if the medical record was not complete. If patients were hospitalized 
more than once, only the first hospital stay in 2004 was considered. 
Demographic information (age, sex, length of hospital stay, residence before and 
after hospitalization), main diagnoses (ICD-10168) and information on drug treatment 
at hospital admission, during hospitalization and at discharge, were retrieved from 
the clinical records and from the hospital discharge letter. Pharmacologically active 
substances were coded according to the Anatomical Therapeutic Chemical (ATC) 
classification.169 Only drugs administered on a regular basis were recorded; drugs 
applied on an on-demand basis were not included. Topically applied drugs with 
presumed topical effects were not evaluated, other than inhaled drugs for the 
treatment of airway diseases. Drugs present at hospital admission were considered 
to have been taken as long-term treatment unless otherwise noted; similarly, a drug 
was considered to be taken for >2 weeks after discharge unless treatment duration 
was specified. 
 
Inappropriate drugs 
PIMs were identified according to the updated Beers criteria published in 2003121 
adapted to drugs available in Switzerland. The original list contains 48 active 
substances or drug classes that should generally be avoided in patients aged  
≥65 years, including some substances for which appropriateness depends on the 
daily dose administered or the duration of the therapy. The Beers criteria also contain 
a list of substances or drug classes that should be avoided in the presence of specific 
underlying diseases or conditions. Several of the drugs listed are not marketed in 
Switzerland and were therefore excluded from the analysis (see appendix). For drug 
classes listed in the Beers criteria, individual substances belonging to this drug class 
that are available in Switzerland, but not listed in the original drug list, were added. 
For example, six benzodiazepines with a half-life of the parent drug or of an active 
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metabolite of ≥20 hours were added to the five long-acting benzodiazepines originally 
listed. Only drugs with a systemic action were checked for inappropriateness 
according to these modified Beers criteria. 
 
Anticholinergic drugs 
Additional to the anticholinergic substances listed in the Beers criteria,121 the list was 
completed with drugs and drug classes defined in other studies as having 
anticholinergic properties.108,170 The final list used in the current study contained the 
following drug classes with anticholinergic properties: conventional antipsychotics,  
tri- and tetracyclic antidepressants, first-generation histamine H1 receptor 
antagonists, anticholinergic antiparkinson agents (biperiden and amantadine) and 
antispasmodics (including belladonna alkaloids). 
 
Statistical analysis 
The Pearson’s chi-square test (for categorical variables) and the independent  
two-sided Student’s t-test (for log-transformed not normally distributed numerical 
variables) were used to detect differences between the two groups regarding 
demographic characteristics, number of diagnoses and number of pharmacologically 
active substances prescribed. The Pearson’s chi-square test was used to compare 
the prevalence of inappropriate medication or anticholinergic drug use between 
medical and geriatric patients at hospital admission, during hospital stay and at 
discharge. The prevalence at discharge was calculated excluding patients who died 
during hospitalization. McNemar’s test was used to analyze potential differences 
between exposure prevalences of PIMs and anticholinergic drugs at hospital 
admission and discharge within each patient group, excluding patients who died 
during hospital stay. This resulted in slightly different prevalences of PIMs and 
anticholinergic drugs at hospital admission. A p-value < 0.05 was considered to be 
statistically significant. All analyses were performed using SPSS for Windows version 
12.0 (SPSS Inc., Chicago, IL, USA). 
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Results 
Patient characteristics 
 
A total of 800 patients aged ≥65 years were included in the analysis. The 
characteristics of the study population are presented in table 8. Main differences 
were higher age (84 versus 76 years; p < 0.001), higher proportion of female patients 
Table 8. Principal characteristics of the study population 
Characteristic Medical ward 
(n = 400) 
Geriatric ward 
(n = 400) 
p-value 
Age (years), median (range) 76 (65-96) 84 (65-98) <0.001 
65-74 years, n (%) 163 (40.8) 33 (8.3)  
75-84 years, n (%) 187 (46.7) 176 (44.0)  
≥85 years, n (%) 50 (12.5) 191 (47.7)  
Sex    
female, n (%) 185 (46.3) 285 (71.3) <0.001 
Number of diagnoses, median (range) 6 (2-9) 7 (2-9) <0.001 
Number of pharmacologically active substances, median (range)   
admission 5.5 (0-20) 6 (0-23) 0.31 
hospitalisation 10 (0-38) 11 (1-28) <0.05 
discharge 6 (0-16) 7 (0-17) 0.67 
Length of hospital stay (days), median (range)  11 (1-59) 16 (2-190) <0.001 
1-7 days, n (%) 123 (30.7) 54 (13.5)  
8-14 days, n (%) 143 (35.7) 109 (27.3)  
15-21 days, n (%) 83 (20.8) 125 (31.3)  
≥22 days, n (%) 51 (12.8) 112 (28.0)  
Residence before admission, n (%)    
community dwelling 358 (89.5) 305 (76.2)  
nursing home 20 (5.0) 71 (17.8)  
transferred from another hospital 20 (5.0) 21 (5.2)  
others 2 (0.5) 3 (0.8)  
Residence after discharge, n (%)    
death 24 (6.0) 42 (10.5)  
community dwelling 267 (66.8) 153 (38.3)  
nursing home 24 (6.0) 104 (26.0)  
transferred to another hospital or rehabilitation center 85 (21.2) 100 (25.0)  
others - 1 (0.2)  
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(71.3% versus 46.3%; p < 0.001) and longer duration of hospital stay (16 versus  
11 days; p < 0.001) in geriatric compared with medical patients, respectively. 
Approximately four times more geriatric patients resided in nursing homes before 
admission, or were discharged to a nursing home after hospitalization, compared 
with medical patients, and almost twice as many patients admitted to the geriatric 
ward died during the hospital stay. 
The main reasons for hospital admission for patients of both study groups were 
diseases of the circulatory system (26.5% in medical and 22.0% in geriatric patients), 
which mainly presented as ischemic heart disease, heart failure or cerebrovascular 
disease. Additional common reasons for hospitalization to the geriatric ward were 
injuries to various parts of the body (12.3%) most often as a result of falls and 
unspecified symptoms (11.3%) such as syncope or collapse.  
The median number of pharmacologically active substances at hospital admission 
was similar for both groups (5.5 in the medical ward versus 6 in the geriatric ward;  
p = 0.31), as was the exposure prevalence to various drug classes. The drug classes 
most often prescribed according to the ATC classification in both patient groups were 
drugs acting on the cardiovascular system (diuretics, ACE inhibitors or angiotensin II 
receptor antagonists and beta-adrenoceptor antagonists), drugs to treat disorders of 
the gastrointestinal tract or metabolic diseases (mineral supplements, 
antihyperglycemic agents and proton pump inhibitors), and drugs affecting the CNS 
system (analgesics, antidepressants and benzodiazepines).  
 
Prevalence of PIMs and anticholinergic drugs at hospital admission 
As shown in figure 6, the prevalence of use of PIMs that should generally be avoided 
according to the Beers criteria was not different between geriatric and medical 
patients (20.8% versus 16.0%, respectively; p = 0.08). A total of 75 and 96 PIMs 
were identified on admission in medical and geriatric patients, respectively (table 9). 
Of these, the most prevalent inappropriate substances in both groups were drugs 
with anticholinergic effects (anticholinergic antispasmodics and biperiden), 
amiodarone and long-acting benzodiazepines. 
Table 9. Number of potentially inappropriate medications (PIMs) that should generally be avoided according to the Beers criteria published in 2003121 identified in the study 
Number of PIMs, n (%) 
admission hospitalization discharge 
Drugs or drug classes 
MW 
75 (100.0) 
GW 
96 (100.0) 
MW 
94 (100.0) 
GW 
77 (100.0) 
MW 
53 (100.0) 
GW 
67 (100.0) 
Anticholinergic antispasmodicsa or anticholinergicsb 18 (24.0) 23 (24.0) 13 (13.8) 16 (20.8) 9 (16.9) 14 (20.9) 
Amiodarone 15 (20.0) 15 (15.6) 24 (25.5) 16 (20.8) 20 (37.7) 15 (22.4) 
Long-acting benzodiazepines 7 (9.3) 10 (10.4) 8 (8.5) 10 (13.0) 5 (9.4) 4 (5.9) 
Estrogens only 5 (6.7) 3 (3.1) 4 (4.3) 3 (3.9) 3 (5.7) 3 (4.5) 
First-generation histamine H1 receptor antagonists 5 (6.7) 4 (4.2) 1 (1.1) 2 (2.6) 1 (1.9) 1 (1.5) 
Paraffin 4 (5.3) 6 (6.3) 9 (9.5) 11 (14.2) 1 (1.9) 5 (7.5) 
Amitriptyline 3 (4.0) 2 (2.1) 5 (5.3) 4 (5.2) 4 (7.5) 4 (5.9) 
Non-COX-selective NSAIDs with long half-life, long-term use of high doses 3 (4.0) 2 (2.1) - - - - 
Barbiturates (except phenobarbital and except to control seizures) 2 (2.7) - 2 (2.1) - 1 (1.9) - 
Doxepin 2 (2.7) - 2 (2.1) - 2 (3.8) - 
Digoxin >0.125 mg/day (except to treat atrial arrhythmia) 2 (2.7) 3 (3.1) - 1 (1.3) - 1 (1.5) 
Short-acting benzodiazepines in high doses 2 (2.7) 7 (7.3) 8 (8.5) 5 (6.5) - 1 (1.5) 
Stimulant laxatives for >2 weeks (except when opioid analgesics are used) 2 (2.7) 8 (8.3) - 4 (5.2) - 11 (16.4) 
Amphetamines and anorexic agents 1 (1.3) - 1 (1.1) - 1 (1.9) - 
Clonidine 1 (1.3) - 4 (4.3) - 2 (3.8) - 
Doxazosin 1 (1.3) 1 (1.0) 1 (1.1) 1 (1.3) 1 (1.9) 2 (3.0) 
Fluoxetine 1 (1.3) - 3 (3.1) - 2 (3.8) - 
Iron >200 mg/day 1 (1.3) 2 (2.1) 4 (4.3) - 1 (1.9) - 
Ergot mesyloids - 4 (4.2) - 1 (1.3) - 3 (4.5) 
Meperidine (pethidine) - 2 (2.1) 4 (4.3) - - - 
Thioridazine - 2 (2.1) - 1 (1.3) - 1 (1.5) 
Indomethacin - 1 (1.0) - 1 (1.3) - 1 (1.5) 
Short-acting nifedipine - 1 (1.0) - 1 (1.3) - 1 (1.5) 
Pentazocine - - 1 (1.1) - - - 
aAnticholinergic antispasmodics: belladonna alkaloids, butylscopolamine, tolterodine, trospium, oxybutynin, isometheptene, drofenine. 
bAnticholinergics: biperiden. 
COX = cyclooxygenase; GW = geriatric ward; MW = medical ward; NSAID = nonsteroidal anti-inflammatory drugs; PIM = potentially inappropriate medication.  
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A total of 79 and 97 PIMs associated with a specific diagnosis were detected on 
admission in 56 medical (14.0%) and 70 geriatric patients (17.5%), respectively 
(table 10, figure 6). Often identified in both groups was the administration of NSAIDs 
or platelet aggregation inhibitors to patients with pre-existing blood clotting disorders 
or anticoagulant therapy, which consisted most often of LMWHs in prophylactic 
doses. Prescription of benzodiazepines to patients with depression or a history of 
syncope and/or falls was also common. 
At admission, 61 substances with anticholinergic properties were identified as having 
been prescribed to 52 medical patients (table 11; figure 6). Of these, tricyclic 
antidepressants were most often prescribed (see table 11). Geriatric patients were 
taking more drugs with anticholinergic properties (81 substances), but overall the 
prevalence was not different compared with medical patients (17.5% versus 13.0%, 
respectively; p = 0.08). Conventional antipsychotics were the most prevalent 
anticholinergic drug class in this population (39.5% of all anticholinergic drugs). 
 
Prevalence of PIMs and anticholinergic drugs during hospital stay 
In medical patients the exposure prevalence of PIMs that should generally be 
avoided was 20.5% during hospital stay (figure 6). Contributing to this nonsignificant 
increase compared with hospital admission was the addition of amiodarone in nine 
patients and the administration of short-acting benzodiazepines in inadequate high 
doses in additional six patients (see table 9). In contrast, the proportion of geriatric 
patients receiving a PIM during hospital stay decreased nonsignificantly from 20.8% 
to 17.3%, despite an increase in the number of pharmacologically active substances 
administered (increasing from a median of 6 to a median of 11 substances per 
patient). In both groups, anticholinergic antispasmodics as well as first-generation 
histamine H1 receptor antagonists were most often stopped.  
There was an almost 3-fold increase in the exposure prevalence of PIMs associated 
with a specific disease in both groups compared with admission, rising to 40.5% in 
medical patients and 51.8% in geriatric patients. This increase is mainly explained by 
Table 10. Number of potentially inappropriate medications (PIMs) associated with a specific underlying disease or condition identified in the study 
Number of PIMs, n(%) 
admission hospitalization discharge 
Disease or condition Drugs or drug classes 
MW 
79 (100.0) 
GW 
97 (100.0) 
MW 
252 (100.0) 
GW 
304 (100.0) 
MW 
51 (100.0) 
GW 
109 (100.0) 
Depression Benzodiazepine use >2 weeks, sympatholytic 
agentsa 
16 (20.3) 27 (27.8) 11 (4.4) 27 (8.9) 10 (19.6) 21 (19.2) 
Blood clotting disorders or 
anticoagulant therapyb 
NSAIDs, platelet aggregation inhibitors 14 (17.7) 20 (20.6) 198 (78.5) 194 (63.8) 25 (49.0) 34 (31.2) 
Bladder outflow obstruction Anticholinergicsc, first-generation histamine H1 
receptor antagonists, anticholinergic 
antispasmodicsd, tricyclic antidepressants 
12 (15.2) 5 (5.2) 9 (3.6) 3 (1.0) 3 (5.8) 2 (1.8) 
Syncope or falls Short-/intermediate-acting benzodiazepines, tricyclic 
antidepressants 
9 (11.4) 22 (22.6) 14 (5.5) 55 (18.1) 5 (9.8) 37 (33.9) 
Arrhythmias Tricyclic antidepressants 6 (7.6) 6 (6.2) 4 (1.6) 6 (2.0) 1 (2.0) 5 (4.6) 
Chronic constipation Calcium channel blockers, tricyclic antidepressants 6 (7.6) 3 (3.1) 5 (2.0) 3 (1.0) 3 (5.8) 3 (2.8) 
Gastric or duodenal ulcers 
(history and actual) 
NSAIDs and aspirin (acetylsalicylic acid) [>325 mg] 6 (7.6) 3 (3.1) - 3 (1.0) - - 
COPD Long-acting benzodiazepines, propranolol 3 (3.8) - 1 (0.4) - 1 (2.0) - 
Parkinson’s disease Metoclopramide, conventional antipsychotics 3 (3.8) - 4 (1.6) 3 (1.0) 1 (2.0) - 
Cognitive impairment Barbiturates, anticholinergicsc, anticholinergic 
antispasmodicsd, centrally acting muscle relaxantse 
2 (2.5) 5 (5.2) 1 (0.4) 5 (1.6) 1 (2.0) 4 (3.7) 
SIADH/hyponatremia SSRIs 2 (2.5) 6 (6.2) 2 (0.8) 4 (1.3) 1 (2.0) 3 (2.8) 
Heart failure High sodium content drugsf - - 3 (1.2) 1 (0.3) - - 
aSympatholytic agents: clonidine.  
bProportion of prescriptions concerning the combination of heparins or low-molecular-weight heparins with NSAIDs or platelet aggregation inhibitors: at admission: MW 9/14 
(64.3%), GW 11/20 (55.0%); during hospitalization: MW 182/198 (91.9%), GW 180/194 (92.8%); at discharge: MW 20/25 (80.0%), GW 28/34 (82.4%). 
cAnticholinergics: biperiden. 
dAnticholinergic antispasmodics: tolterodine, trospium, oxybutynin. 
eCentrally acting muscle relaxants: tizanidine, baclofen. 
fHigh sodium content drugs: sodium polystyrene sulfonate, piperacillin sodium/tazobactam sodium. 
COPD = chronic obstructive pulmonary disease; GW = geriatric ward; MW = medical ward; SIADH = syndrome of inappropriate antidiuretic hormone; SSRI = selective 
serotonin reuptake inhibitor. 
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the addition of LMWHs for thrombosis prophylaxis to an existing therapy of platelet 
aggregation inhibitors (see table 10). In geriatric patients, the increase was also due 
to initiating treatment with short-acting benzodiazepines in patients with a history of 
falls or syncope. 
There was also an increase in the exposure prevalence of drugs with anticholinergic 
properties by a factor of 2.6 in geriatric patients. This increase was largely explained 
by the prescription of haloperidol to 150 patients (37.5%), mainly for delirium 
prophylaxis or treatment. Use of conventional antipsychotics, mainly pipamperone or 
haloperidol, also increased in medical patients; overall, however, use of 
anticholinergic drugs was significantly lower in medical patients than in geriatric 
patients (16.5% versus 45.5%, respectively; p < 0.001). 
 
Prevalence of PIMs and anticholinergic drugs at hospital discharge 
During hospital stay, 24 medical patients and 42 geriatric patients died and were 
therefore excluded from the analyses at hospital discharge. The prevalence of 
treatment with inappropriate substances in the remaining 358 patients discharged 
from the geriatric ward was 15.9% compared with 22.1% at admission (p < 0.05). In 
comparison, there was no difference between the prevalence of treatment with 
inappropriate substances at discharge and admission in the remaining 376 medical 
patients (13.3% versus 16.0%, respectively; p = 0.10). Overall, there was no 
difference in the exposure prevalences of PIMs between geriatric and medical 
patients at discharge (figure 6). The most often prescribed inappropriate drugs or 
drug classes at discharge for both groups were the same as at admission, namely 
amiodarone, anticholinergic antispasmodics including the anticholinergic 
antiparkinson agent biperiden, long-acting benzodiazepines and, in geriatric patients, 
paraffin and stimulant laxatives (table 9).  
At discharge, the exposure prevalence of PIMs associated with a specific disease 
was significantly higher in geriatric than in medical patients (23.7% versus 11.7%, 
respectively; p < 0.001). In geriatric patients, this exposure prevalence was 5.9% 
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higher than at hospital admission (p < 0.05). A reason for this finding was the higher 
number of benzodiazepines prescribed to patients with a history of falls/syncope or 
depression. Geriatric patients were not only more often hospitalized due to syncope 
or falls, they were also prescribed more benzodiazepines at discharge than were 
medical patients (111 versus 55 times, respectively), which may explain this result. 
Compared with admission, geriatric patients were also discharged more often with 
platelet aggregation inhibitors and LMWHs in prophylactic doses (see table 10). 
At discharge, the prevalence of geriatric or medical patients treated with 
anticholinergic drugs was not significantly different (16.5% versus 12.2%, 
respectively; p = 0.10). There were no significant changes in prevalence of 
 
Figure 6. Changes in prevalence of use of potentially inappropriate medications (PIMs) and anticholinergic 
drugs in patients during hospital stays in general medical or geriatric wards. Total PIMs = general PIMs and/or 
diagnosis-associated PIMs. * indicates significant difference between medical and geriatric patients (p < 0.05). 
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anticholinergic drug use compared with use on hospital admission (figure 6). 
Conventional antipsychotic agents were identified as the anticholinergic drug class 
prescribed most often at discharge in both groups. 
 
 
 
Discussion 
The exposure prevalences of PIMs which should generally be avoided found in this 
study on both wards (13.3-20.5% on the medical ward and 15.9-20.8% on the 
geriatric ward) were in accordance with prevalences ranging from 5.8% to 25.7% 
found in other studies using the Beers criteria published in 2003.122-124 However, 
comparisons with other studies must be interpreted carefully. Reasons for this 
include differences in patient settings, interpretation of the Beers criteria, and 
country-specific use of drugs. Inappropriate drugs often identified in other studies 
were nitrofurantoin, long-acting benzodiazepines, short- to intermediate-acting 
benzodiazepines at high doses, amitriptyline, doxazosin, amiodarone and 
estrogens.122-124 These findings are quite similar to those of the present study, in 
which amiodarone, long-acting benzodiazepines, anticholinergic antispasmodics, 
paraffin and estrogens were the most prevalent inappropriate drugs. 
Table 11. Number of drugs or drug classes with anticholinergic properties identified in the study 
 Number of anticholinergic drugs, n (%) 
 admission hospitalization discharge 
 
MW 
61 
(100.0) 
GW 
81 
(100.0) 
MW 
80 
(100.0) 
GW 
207 
(100.0) 
MW 
53 
(100.0) 
GW 
65 
(100.0) 
Tricyclic antidepressants 23 (37.7) 19 (23.5) 23 (28.7) 16 (7.7) 16 (30.2) 12 (18.5) 
Anticholinergic antispasmodicsa 16 (26.2) 22 (27.2) 11 (13.8) 16 (7.7) 8 (15.1) 14 (21.5) 
Conventional antipsychotics 16 (26.2) 32 (39.5) 38 (47.5) 171 (82.6) 26 (49.0) 36 (55.4) 
First-generation histamine H1 receptor 
antagonists 
4 (6.6) 4 (4.9) 4 (5.0) 2 (1.0) 2 (3.8) 1 (1.5) 
Anticholinergic antiparkinson agents 
(biperiden and amantadine) 
2 (3.3) 4 (4.9) 4 (5.0) 2 (1.0) 1 (1.9) 2 (3.1) 
atolterodine, trospium, oxybutynin, belladonna alkaloids, butylscopolamine. 
GW = geriatric ward; MW = medical ward. 
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Only a few studies have assessed the use of inappropriate drugs related to 
underlying diseases. The reported prevalences found in an outpatient setting ranged 
between 3.1% and 5.1%,122,171,172 which are lower than the prevalences found in this 
study (11.7-40.5% in medical and 17.5-51.8% in geriatric patients). These differences 
may be explained by inclusion of hospitalized patients in this study, in whom the 
combination of platelet aggregation inhibitors with unfractionated heparin or LMWHs, 
especially at prophylactic doses, is common, but which is considered as potentially 
inappropriate according to the Beers criteria published in 2003.121 To our knowledge, 
only one study including ambulatory patients and analyzing inappropriate drug use in 
relation to comorbidities according to the 2003 Beers criteria has been published.122 
As observed in our study, use of short- to intermediate-acting benzodiazepines in 
patients with a history of falls or syncope was common, as was administration of 
NSAIDs to patients with a history of gastric or duodenal ulcer. 
It was expected that geriatricians might be more aware of problematic drugs and 
PIMs for the treatment of elderly patients, which would lead to a significant reduction 
in use of those drugs during hospitalization. Indeed, the prevalence of use of PIMs 
generally to be avoided was 6.2% lower in patients discharged from the geriatric 
ward compared with admission, whereas there was no difference in exposure 
prevalence in comparison with patients discharged from the medical ward. Our 
finding supports the findings of Laroche et al.,166 who reported that the prevalence of 
PIM use was reduced by about 24% during hospitalization on geriatric wards. 
However, another study comparing the prevalence of PIM use in elderly patients 
hospitalized either on a geriatric or medical ward failed to show a significant 
reduction in PIM use in geriatric patients at discharge.167 This may be explained by 
the small sample size. Out of 127 patients hospitalized on the geriatric ward,  
13 patients (10%) were admitted and five patients (4%) discharged with PIMs, 
whereas of 127 medical patients, 12 (9%) and seven patients (6%) had PIMs at 
admission and discharge, respectively. In our study, an additional 21 geriatric 
patients (5.9%) were discharged with PIMs according to underlying diseases 
compared with hospital admission. One reason for this finding was the frequent 
administration of benzodiazepines to patients with a history of falls or syncope, which 
is a risk factor for falls. Not only were geriatric patients more often hospitalized due to 
syncope or falls, they were also more often prescribed short- to intermediate-acting 
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benzodiazepines at discharge compared with medical patients, which may explain 
this finding. The indications for prescription of these benzodiazepines were not 
assessed. 
Hospitalization may increase the frequency of starting benzodiazepine treatment.173 
One reason for this is that hospital admission may provoke anxiety and insomnia. 
Insomnia is a common problem in the elderly and all available hypnotics, not only 
benzodiazepines but also zolpidem, may increase the risk of falls and 
fractures.49,118,119,174-176 Furthermore, short-acting benzodiazepines appear to be no 
safer in this respect than longer-acting agents;119,176 and they should therefore be 
prescribed only very restrictively to elderly patients, especially at hospital discharge. 
Newer compounds such as zopiclone, zolpidem or zaleplon are considered to be 
safer, because of their short half-lives and more selective pharmacological activities 
at the benzodiazepine-1 receptor. However, definitive proof of their safety in relation 
to falls in the elderly is lacking so far. In the elderly, half of the recommended adult 
dose should be prescribed.49,174 In addition, short-acting benzodiazepines should not 
be considered as first-line treatment in anxious depressed elderly patients, because 
of the additional risk of cognitive impairment.51,177 Adequate treatment with 
antidepressants such as SSRIs represents a safer option in these patients.51,177 
Use of drugs with anticholinergic effects in elderly patients has been associated with 
an increased risk of delirium and cognitive decline.108,165,178 Additional factors 
contributing to delirium are dementia, severe comorbidities, metabolic disorders 
(hypoalbuminemia, dehydration), surgery, infections, environmental factors 
(unfamiliar environment, stress) and use of centrally active drugs such as 
benzodiazepines and opioids.178-180 The prevalences of use of drugs with 
anticholinergic effects found in the present study (12.2-17.0% on medical wards and 
16.5-45.0% on geriatric wards) were consistent with those reported in other studies, 
which ranged between 10% to 42%, depending on the population setting 
evaluated.108,170 During hospital stay, 37.5% of geriatric patients were treated with 
haloperidol, a drug with anticholinergic properties. However, because of its high 
antipsychotic potency, the risk of anticholinergic effects with this drug is low. 
Haloperidol at low doses (0.25-0.5 mg/day) is recommended as prophylaxis for 
delirium in hospitalized, elderly patients, in whom this condition may occur in 10-38% 
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of patients.178-180 In contrast to findings from the study by Saltvedt et al.,167 no 
difference in the prevalence of anticholinergic drug use between admission and 
discharge was found in geriatric or medical patients in the current study.  
Our study has several limitations. Direct comparison of the prevalence of use of PIMs 
between the two study populations may be limited by differences in age, proportion of 
female patients, reason for hospitalization, differences in underlying diseases, and 
length of hospital stay (table 8). It is known from other studies that the number of 
drugs per patient is a strong risk factor for the use of PIMs,123,181,182 but this 
parameter was not different between geriatric and medical patients in our study. Age 
and sex were often not significant risk factors in multivariate analyses,181,182 and 
higher age in one study was actually associated with reduced risk for PIMs.123 
Therefore, if the prevalence of PIM use had been influenced by the characteristics of 
the two populations studied, underlying diseases and reasons for hospitalization  
(e.g. frequent history of falls in geriatric patients) would have been the most likely 
factors. 
Because of the retrospective study design, the clinical consequences of intake of 
PIMs or anticholinergic drugs are unknown. Some studies have investigated 
outcomes following administration of PIMs and found an association with poorer self-
perceived health status, higher healthcare costs and a higher number of inpatient, 
outpatient or emergency room visits.183-185 Other studies, however, failed to show any 
association between intake of PIMs and an increase in number of outpatient visits, 
increased healthcare utilization or decrease in quality of life.186,187 Administration of 
inappropriate drugs according to the Beers criteria has not been associated with 
higher mortality,85,185,188 except in two studies.164,181 One of these two studies used a 
combined endpoint, however, consisting of hospitalization, emergency department 
visit and death.181  
Because of the limitations of the Beers criteria, the results of this study have to be 
interpreted carefully. The Beers criteria are a useful tool for evaluating drug 
prescriptions in elderly patients with the intention to improve prescribing. However, 
the criteria are based on expert opinions and not on an evidence-based 
methodology.189,190 Even if the drugs in the Beers list may be considered as 
inappropriate, they are not contraindicated per se, and their benefit-to-risk ratio must 
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be assessed in the context of the individual patient’s clinical condition.189,190 
However, the Beers criteria do not propose an alternative therapy with a better 
tolerability and/or outcome than the drugs listed as inappropriate.189  
In the Beers criteria, concomitant treatment with platelet aggregation inhibitors is 
defined as potentially inappropriate in patients receiving anticoagulant therapy, 
because of an increased risk of hemorrhage.121 This risk has been demonstrated in a 
number of studies.191-194 However, in patients with acute coronary syndrome, initial 
treatment with unfractionated heparin or LMWHs in combination with low-dose aspirin 
(acetylsalicylic acid) is associated with reductions in recurrent myocardial infarction 
and death.193 In patients, assessment of the individual risks and benefits, taking into 
account the individual clinical situation is important. The dosages of the anticoagulant 
used should be adjusted according to renal and hepatic function, and effects 
monitored closely, as high doses are associated with increased risk of 
bleeding.104,191,195-197 Most of the patients comedicated with platelet aggregation 
inhibitors and anticoagulants in our study were treated with LMWHs for thrombosis 
prophylaxis during hospitalization because most hospitalized elderly patients are at 
increased risk of venous thromboembolism.104,198 If such patients are taking 
prophylactic rather than therapeutic dosages of LMWHs, they may be exposed to 
only to a slightly increased risk of bleeding, because of the dose dependency of this 
ADR.199 However, the Beers criteria do not differentiate between prophylactic and 
therapeutic use of heparin or LMWHs in combination with platelet aggregation 
inhibitors. 
Another example of a drug commonly identified as potentially inappropriate in the 
current study according to the Beers criteria is amiodarone, because of its potential 
to prolong the QT interval and induce torsade de pointes. These two ADRs are 
considered to be dose dependent. However, there is no evidence that age is 
associated with a significant alteration in the pharmacokinetics of amiodarone or that 
the risk of cardiac adverse events is increased in the elderly.200 Prolongation of the 
QT interval and torsade de pointes occur in <1% of the patients treated with 
amiodarone.201,202 In comparison, studies have shown beneficial effects of 
amiodarone in the treatment of sustained ventricular tachyarrhythmias and/or atrial 
fibrillation in patients after myocardial infarction, especially in patients with left 
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ventricular dysfunction.201,203 In the presence of ventricular tachyarrhythmias, elderly 
or critically ill patients may profit from treatment with amiodarone, when the 
implantation of a cardioverter defibrillator is not possible.201,203 
 
 
Conclusion 
The results of this study show that the use of inappropriate drugs according to the 
Beers criteria is common on both medical and geriatric wards. Compared with 
internists, geriatricians have a better understanding for PIMs that should generally be 
avoided. On the other hand, similar to internists, geriatricians did not reduce the 
prevalence of PIM use associated with a specific diagnosis or use of anticholinergic 
drugs. 
Many of the drugs identified as inappropriate according to the Beers list in this study 
may be considered to be appropriate, when taking into account the patient’s clinical 
condition. Examples of such drugs include amiodarone or the combination of 
anticoagulants or LMWHs with platelet aggregation inhibitors. The Beers criteria are 
a useful tool for identifying potential pharmacological problems in the elderly, but their 
use in clinical practice is limited because age per se is not a good indicator of the 
individual’s health status and the elderly are not a homogeneous population. It is 
essential to determine the benefit-to-risk ratio of a drug therapy individually for each 
patient, taking into account the clinical condition of the patient, the degree of 
impairment of hepatic and/or renal function, and the potential for interactions with 
existing drug therapies. In addition, elderly patients, especially those taking PIMs, 
should be monitored closely for potential ADRs. 
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Appendix 
Drugs listed in the Beers criteria published in 2003,121 but not marketed in 
Switzerland are: carisoprodol, chlorpheniramine, chlorzoxazone, cyclobenzaprine, 
cyproheptadine, desiccated thyroid, dicyclomine, disopyramide, ethacrynic acid, 
guanadrel, guanethidine, halazepam, hyoscyamine, isoxsurpine, mesoridazine, 
metaxalone, methamphetamine, methocarbamol, methyltestosterone, orphenadrine, 
oxaprozin, pemolin, perphenazine-amitriptyline, prazosin, propantheline, 
propoxyphene, pseudoephedrine, quazepam, tacrine, thiothixene, ticlopidine, 
trimethobenzamide and tripelennamine. 
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Abstract 
Objective: To report the occurrence of lithium intoxication in a patient with bipolar 
disorder after adding rofecoxib to the medication regimen. 
Case summary: A 68-year-old woman with bipolar disorder under long-term 
treatment with lithium, carbamazepine, pipamperone, and mirtazapine was 
prescribed rofecoxib 25 mg twice daily for the treatment of leg pain. Within one week, 
she showed progressive hypokinesia and tremor, which was treated with propranolol. 
Subsequently, she developed bradycardia, necessitating treatment with 
isoproterenol. Her lithium serum concentration had doubled compared with those 
before rofecoxib, and her renal function had deteriorated. After stopping lithium and 
rofecoxib, her laboratory values and neurologic signs improved or normalized within 
2 days. An objective causality assessment revealed a probable relationship between 
concomitant use of the drugs and the resulting symptoms. 
Discussion: As of May 24, 2004, only 3 cases of reversible lithium intoxication as a 
result of a possible interaction with rofecoxib or celecoxib have been previously 
reported. The mechanism of the interaction between lithium and cyclooxygenase 
(COX) 2 selective inhibitors is most probably related to inhibition of renal synthesis of 
prostaglandins, which are important for the maintenance of renal perfusion and 
tubular function. Impairment of renal blood flow, leading to a decrease in the 
glomerular filtration rate, and increased proximal tubular absorption are the most 
likely mechanisms by which COX-2 selective inhibitors reduce lithium clearance. 
Conclusions: Coadministration of rofecoxib and lithium may result in life-threatening 
lithium intoxication, especially in patients with a preexisting decrease in renal function 
and/or decreased intravascular volume. 
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Introduction 
Selective COX-2 inhibitors are frequently used to treat acute and chronic 
inflammatory diseases and pain because they appear to have a lower risk for 
gastrointestinal toxicity compared with conventional NSAIDs.204 However, the 
expectation that COX-2 selective inhibitors could also reduce untoward renal effects 
compared with conventional NSAIDs could not be met.205 Considering reviews about 
the effects of selective COX-2 inhibitors on the kidneys, it appears that their 
nephrotoxicity is similar to that of nonselective COX-2 inhibitors.205,206 COX-2, initially 
thought to be expressed primarily in inflamed tissues, has been shown to also play a 
role in physiologic processes, including maintenance of renal function. This is 
particularly the case in conditions involving increased renal prostaglandin 
dependence such as decreased sodium intake, volume depletion, renal artery 
stenosis, liver cirrhosis, and heart failure.205,207 Renal expression of COX-2 is 
increased in the conditions mentioned above to maintain renal blood flow and GFR, 
as well as tubular functions involved in sodium, potassium, and water homeostasis. 
Acute renal failure associated with COX-2 selective inhibitors has been reported in 
patients with the same risk factors as reported for conventional NSAID-associated 
renal adverse effects.205,207 
Lithium is an established treatment for patients with bipolar disorders. Due to its 
toxicity, the lithium serum concentration must be maintained within a narrow range. 
Neurologic manifestations of toxicity are dose dependent and may begin with 
nausea/vomiting, drowsiness, lethargy, coarse hand tremor, and muscular weakness, 
followed by nystagmus, ataxia, confusion, dysarthria, and myoclonic twitches, finally 
resulting in impaired consciousness, seizures, coma, and death. Electrocardiographic 
changes (flat or inverted T waves) may also be observed.208 
The pharmacokinetic properties of lithium and its DDIs have been reviewed.208 
Lithium is absorbed rapidly and completely from the upper gastrointestinal tract, is 
not bound to plasma proteins, is distributed evenly in the body water (showing a 
volume of distribution of 0.7 L/kg), and is eliminated almost entirely by the kidneys. 
Lithium is filtered by the glomerulus, and approximately 75% of the amount filtered is 
reabsorbed in parallel to sodium, mostly in the proximal tubule.209 Several drug 
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classes, including diuretics (particularly thiazides), ACE inhibitors, and NSAIDs have 
been shown to decrease renal lithium clearance and increase lithium serum 
concentrations.210 
Since selective COX-2 inhibitors show effects on the kidney similar to those of 
conventional NSAIDs,205,207 COX-2 inhibitors could also decrease renal lithium 
clearance. However, to the best of our knowledge, only a few cases of possible 
interactions of lithium with celecoxib211,212 or rofecoxib213 have so far been reported in 
the literature. Most recently, Phelan et al.214 described 18 patients with increased 
serum lithium concentrations associated with the addition of a COX-2 inhibitor to their 
medication regimen; these cases had been reported to the Food and Drug 
Administration. 
 
 
Case report 
A 68-year-old woman with a bipolar disorder, who had been on a stable treatment 
regimen with lithium 200 mg twice daily for 12 years (serum concentrations  
0.74 - 0.94 mEq/L), was hospitalized due to pain in the left leg after an accidental fall  
3 months earlier. Additionally, she had been prescribed carbamazepine 400 mg twice 
daily (for 12 years), pipamperone 60 mg daily and zopiclone for sleeping (for 6 
years), and mirtazapine 30 mg daily (for 3 months). There was no history of previous 
use of NSAIDs or aspirin. X-ray investigations revealed osteochondrosis at L5-S1, 
but no direct cause for the pain in the left leg. Physical examination revealed 
kyphosis of the thoracic vertebral column and hyperlordosis. Since the woman had 
pain upon compression of the lumbar and pelvic musculature, a diagnosis of 
lumbospondylogenic syndrome was made. Additional diagnoses were chronic 
pancytopenia of unknown origin and impaired renal function (reason not known, first 
diagnosis 3 years before presentation), with calculated creatinine clearance 
approximately 40 mL/min. On the day of hospitalization, her serum creatinine 
concentration was 1.25 mg/dL, heart rate 68 beats/min, and blood pressure  
90/60 mm Hg, a normal value for her. To treat the pain, administration of rofecoxib  
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25 mg twice daily was started. On the second day of hospitalization, the patient’s 
serum lithium concentration was just above the upper therapeutic range (0.81 mEq/L, 
range 0.5-0.8). On day 3, she started to develop hand tremor. She was examined by 
a neurologist, who diagnosed an extrapyramidal syndrome consisting of tremor, rigor, 
and hypokinesia, possibly associated with neuroleptic treatment. On day 8 at 11:00, 
the patient was treated with a single dose of propranolol 40 mg because the tremor 
had worsened. In the late afternoon, approximately 6 hours after administration of 
propranolol, the patient reported headache, nausea, and vomiting. An 
electrocardiogram showed sinus bradycardia and intermittent complete 
atrioventricular block with sinus arrests up to 4 seconds, but no signs of heart failure. 
She was transferred to the intensive care unit (ICU) for supervision. 
 
Table 12. Clinical signs and laboratory values in a patient treated with lithium and rofecoxib 
 
Day 
Parameter 1a 2 7 8b 9 
(01:45) 
9 
(12:51) 
10 
(06:45) 
10 
(13:30) 
Lithium concentration 
(therapeutic range: 0.5-0.8 mEq/L) 
 0.81  1.67  1.32 0.92  
Carbamazepine concentration 
(therapeutic range: 4-10 mg/L) 
     12.7   
SCr concentration 
(reference range: 0.5-1.0 mg/dL) 
 1.25  1.77 1.58 1.59 1.33 1.24 
Calculated Clcr (mL/min)  41  28  28 38 41 
Potassium level 
(reference range: 3.5-5.0 mEq/L) 
 4.3  5.4 5.3 4.3 4.5 4.3 
Blood pressure (mm Hg)  90/60 120/60 120/68 90/40 102/68 112/90 118/48 104/54 
aRofecoxib started. 
bSingle oral dose of propranolol was administered; rofecoxib and lithium were stopped. 
Clcr = creatinine clearance; Scr = serum creatinine. 
 
Upon admission to the ICU, her heart rate was 40 beats/min, and blood pressure was 
90/40 mm Hg (table 12); no atrioventricular block or signs of heart failure were noted. 
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She was alert, her speech was slurred, she exhibited tremor of her hands at rest, and 
intermittent periods of drowsiness occurred. Neither nystagmus nor asterixis was 
present. Intravenous isoproterenol was administered, resolving bradycardia and 
increasing blood pressure. During the whole episode, the patient’s urine output had 
been >70 mL/h, indicating that renal perfusion had been maintained. In comparison 
with the value obtained 6 days earlier, the lithium serum concentration had doubled 
(1.67 mEq/L), reaching the toxic range. As shown in figure 7, this increase could 
partially be explained by a drop in the clearance of lithium since the calculated 
creatinine clearance was 27 mL/min at this time. An electrocardiogram revealed 
inversion of the T wave, compatible with increased lithium serum concentration. 
Rofecoxib and lithium were stopped on day 8, and carbamazepine was stopped on 
day 9. After rofecoxib was stopped, the creatinine clearance reached the 
prehospitalization level over 2 days, with a parallel fall in the serum lithium 
concentration to 0.92 mEq/L over that same period (figure 7). 
 
 
Figure 7. Lithium and creatinine serum concentrations and creatinine clearance during concomitant rofecoxib 
therapy. 
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The patient was discharged from the ICU on the tenth day of hospitalization (3 d after 
entering the ICU) with a normal heart rate, normal electrocardiogram, and clearly 
improved tremor. After the reintroduction of lithium and carbamazepine at the same 
dosage as before and initiation of paracetamol as analgesic, the patient had no 
further complications. Using the Naranjo probability scale, a probable relationship 
was found for lithium intoxication and an interaction between lithium and rofecoxib.215 
 
 
Discussion 
Three cases of an interaction between COX-2 inhibitors (celecoxib or rofecoxib) with 
lithium, resulting in increased serum lithium concentrations and lithium toxicity, have 
been reported in detail.211-213 All of these cases are comparable with the one we 
describe here. All patients were elderly, had been treated with lithium and other 
drugs for many years, and had maintained serum lithium concentrations within the 
therapeutic range. All patients developed signs of lithium intoxication (confusion, 
tremor, gait disturbance) leading to hospitalization a few days up to 3 months after 
beginning treatment with a COX-2 inhibitor. In all patients, toxic serum lithium 
concentrations (>1.2 mEq/L) and elevated serum creatinine values were measured. 
After withdrawal of lithium and the COX-2 inhibitor, all patients recovered within one 
week, and the lithium and creatinine serum concentrations returned to the values 
prior to administration of the COX-2 inhibitor. Our patient was also treated with 
carbamazepine, which has been reported to have a pharmacodynamic interaction 
with lithium.208 Such an interaction may therefore have contributed to the neurologic 
symptoms experienced by our patient. 
A case series published in abstract form included 10 patients on lithium therapy who 
were treated with rofecoxib 50 mg for 5 days due to various pain states.216 In 9 of 
these patients, the serum lithium concentrations increased, and one of these patients 
developed signs of mild lithium toxicity. After stopping treatment with rofecoxib, the 
lithium concentrations of all patients returned to near baseline. 
Case report: Lithium intoxication as a result of an interaction with rofecoxib 
77 
Of 20 cases of lithium intoxication reported spontaneously to the Swiss Agency for 
Therapeutic Products between 1996 and 2003, 2 patients (including ours) were 
treated with rofecoxib (10% of the reported cases) and 6 patients received 
conventional NSAIDs (ibuprofen, diclofenac, mefenaminic acid, aspirin; 30% of the 
reported cases). Most patients were on stable, long-term therapy with lithium, and 
signs and symptoms of lithium intoxication occurred a few days after introduction of 
the NSAID or COX-2 inhibitor. Three patients (including ours) had relevant 
comorbidities, such as preexisting renal failure and/or dehydration. 
Most recently, Phelan et al.214 found 18 possible cases of lithium interacting with 
COX-2 inhibitors: 13 with rofecoxib and 5 with celecoxib. The increase of the serum 
lithium concentration after the addition of celecoxib ranged from 56% to 99% and, 
after rofecoxib was introduced, from 58% to 448%. The adverse effects were 
consistent with the symptoms of lithium intoxication. Most patients recovered after 
discontinuation of the COX-2 inhibitor and/or reduction of the lithium dosage. 
Unfortunately, the case series lacks information about preexisting renal disorders, 
concomitant drug use, and medical history of the patients. 
As mentioned above, approximately 75% of the filtered lithium ion is reabsorbed by 
the renal tubules and collecting ducts. The major part of this reabsorption occurs in 
the proximal tubule (up to 70% of the lithium filtered),209,217 and minor amounts are 
reabsorbed in the loop of Henle and the collecting ducts.218,219 Although the 
mechanism of proximal tubular reabsorption of lithium is debated,220,221 it competes 
with the reabsorption of sodium and may be driven by the sodium-hydrogen 
exchanger209. This is compatible with the observation that administration of sodium to 
patients with lithium intoxication is associated with increased lithium clearance. 
Reabsorption of lithium in the loop of Henle is bumetanide sensitive and proposed to 
be accomplished by the sodium-potassium-chloride cotransporter219 and, in the 
collecting ducts, by the sodium channel.209 Dehydration is associated with reduced 
clearance of lithium primarily due to impaired renal perfusion resulting in reduced 
lithium filtration, but also due to increased reabsorption of lithium.209,210,222 It has been 
shown that age-related changes in the glomerular filtration rate may explain the 
prolonged plasma half-life of lithium in the elderly.223  
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The interaction between NSAIDs and lithium is well established and, apparently, the 
effect on lithium clearance differs among the individual NSAIDs (e.g., the effect of 
aspirin and sulindac is less pronounced than with other NSAIDs).210,224 However, the 
mechanism of the interaction between NSAIDs and lithium leading to increased 
lithium serum concentrations is not fully understood.136 COX-2 is constitutively 
expressed in the thick ascending limb of the kidney, in interstitial cells of the papilla, 
and in cells of the macula densa.205,207 Although the role of COX-2 in the kidney is 
not completely clear, it seems to be important for the regulation of the renal function, 
more so than COX-1.225 Vasodilating prostaglandins, predominantly prostaglandin E2 
(PGE2), play an important role in the maintenance of renal blood flow, particularly in 
patients with decreased sodium intake, volume depletion, renal artery stenosis, or 
heart failure.205,207 Administration of an NSAID or COX-2 inhibitor to such patients 
may therefore cause a sharp decrease in renal blood flow, possibly leading to acute 
renal failure.206,207,210 In addition, PGE2 may play also a role in controlling renal salt 
and water reabsorption, and reduced renal PGE2 levels may be associated with 
increased reabsorption of sodium and lithium in patients treated with 
NSAIDs.206,210,224 
 
 
Summary 
Similar to nonselective COX inhibitors, the administration of COX-2 selective 
inhibitors to patients treated with lithium may result in increased lithium serum 
concentrations and lithium intoxication. The lithium serum concentration may 
increase rapidly (within days) after introduction of the COX-2 selective inhibitors. 
Patients at risk are those with conditions of increased prostaglandin dependence of 
renal perfusion, such as those with reduced sodium intake, volume depletion, 
impaired renal function, liver cirrhosis, or heart failure. 
In patients treated with lithium, NSAIDs or COX-2 inhibitors should therefore be 
avoided, particularly in the presence of risk factors. If anti-inflammatory treatment 
with COX-2 inhibitors or NSAIDs is considered to be necessary in such patients, 
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lithium concentrations should be monitored closely and lithium doses should be 
adjusted to lower levels accordingly. If anti-inflammatory treatment is stopped, the 
reverse reaction will occur, and lithium doses should be increased to prevent 
exacerbation of bipolar disorder. 
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Discussion 
Because of demographic aging medical care of elderly patients is an important issue. 
One aspect of special concern is the higher risk for ADRs associated with medical 
treatment. This increased risk may not only be ascribed to age-related physiological 
changes, but is also directly associated with specific drug classes prescribed to the 
elderly.226 
In the first study age-related differences in the prevalence of pDDIs were analyzed in 
a high risk population for polymorbidity and polypharmacy, in dyslipidemic patients 
treated with a statin. As expected, patients aged ≥75 years had a significantly higher 
prevalence of pDDIs compared to patients aged ≤54 years. Factors mainly 
responsible for this finding were the higher prevalence of underlying diseases leading 
to a higher number of pharmacologically active substances prescribed as well as a 
higher number of substances per diagnosis prescribed. This result confirms that 
polypharmacy in comorbid patients is an important risk factor for pDDIs that may lead 
to ADRs.89,129 It is therefore advised to reduce the number of drugs prescribed, 
whenever possible. Arrhythmia and heart failure have been identified as risk factors 
for pDDIs in patients aged ≥75 years. These diagnoses are surrogate parameters for 
the drugs used in the treatment of heart failure and arrhythmias that were involved in 
statin and non statin pDDIs such as amiodarone, digoxin, ACE inhibitors, oral 
anticoagulants, diltiazem and verapamil. The risk for ADRs resulting from the pDDIs 
identified could in most cases be lowered by dose adjustment, close monitoring or 
selection of an alternative drug. As an example, pDDIs involving atorvastatin or 
simvastatin could often be avoided when pravastatin that is not significantly 
metabolized by CYP isozymes in the liver is given instead. On the other hand, it has 
to be considered that atorvastatin and simvastatin are more potent at moderate 
doses than pravastatin and produce a greater reduction in low-density lipoprotein 
cholesterol concentrations.227,228 Although myopathy in patients who receive statin 
therapy is estimated to occur only in 0.1-0.5% of the patients and rhabdomyolysis in 
0.04-0.2% of the patients, DDIs have been suspected to be the cause in 55-58% of 
the cases of rhabdomyolysis.155,229,230 DDIs with statins, especially with simvastatin 
and atorvastatin, known to increase the risk for rhabdomyolysis should therefore be 
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avoided. The relevance of the results of the first study may be limited, because only 
pDDIs were evaluated and not ADRs resulting from these pDDIs. On the other hand, 
the pDDIs identified in our study have to be considered by physicians when 
prescribing drugs to elderly patients, because they are associated with a potentially 
serious outcome, because in the elderly other predisposing factors may further 
enhance the risk for ADRs, and lastly because pDDIs are a preventable risk. 
Certain drugs or drug classes are directly associated with a higher risk for ADRs, 
especially in the elderly.226 This was investigated in the second study, where the 
prevalence of PIM and anticholinergic drug use was assessed in elderly patients 
hospitalized either on a medical or geriatric ward. Compared to medical patients, 
patients discharged from the geriatric ward were significantly less PIMs prescribed 
than at admission. Similarly, also Laroche et al.166 could show a significant decrease 
in the prevalence of PIM use in patients after hospitalization to an acute medical 
geriatric unit. These results show that patients may profit being treated by 
geriatricians with special knowledge of problems in the medical care of elderly 
patients. However, this possible benefit has yet to be confirmed in other studies. It 
has also been shown that clinical pharmacists may have an impact on appropriate 
prescribing and reduction of polypharmacy.231,232 The strength of our second project 
was that also PIMs considering underlying diagnoses were evaluated, because most 
other studies did not include this aspect of the Beers criteria. The study revealed that 
geriatric patients were significantly more often prescribed PIMs considering 
underlying diseases at discharge than at admission. This was related to the frequent 
prescription of short-acting benzodiazepines to geriatric patients with a history of falls 
or syncope. Falls are a serious problem in the elderly and associated with increasing 
morbidity and mortality.120 It is hypothesized that the newer compounds such as 
zopiclone, zolpidem or zaleplon may be safer for the elderly in half of the 
recommended adult dosage, because of their short half-lives and more selective 
pharmacological activities at the benzodiazepine-1 receptor.174 However, their safety 
concerning the risk of falls has not been proven yet.174 Elderly patients are also more 
vulnerable to anticholinergic effects.233 Nevertheless, the overall prevalence of drugs 
with strong anticholinergic effects has neither been reduced in geriatric nor medical 
patients throughout hospital stay. However, especially the combination of 
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anticholinergic drugs, or the administration of anticholinergic drugs to patients with 
dementia should be avoided because of a higher risk for delirium.77,112,165 
The Beers criteria have been shown to be a valuable tool to identify potential 
problems concerning the selection of drugs in the elderly, but they have also several 
limitations. In our study, one of the most common drugs identified as potentially 
inappropriate in both patient groups was amiodarone. But reviewing the literature it is 
not clear, why amiodarone has been listed as potentially inappropriate.201,203 Also the 
classification of amitriptyline as potentially inappropriate without any limitation is 
questionable as amitriptyline has shown to be effective in the treatment of pain 
syndromes at low doses.201,203,234 Lower doses may also be associated with a lower 
risk for anticholinergic effects.235 Nevertheless, the list may help physicians to be 
aware of drugs associated with a higher risk for ADRs, but the decision to prescribe a 
certain drug must be made based on the patient’s individual clinical situation. Other 
criteria published in the literature for the evaluation of appropriate prescribing such as 
the criteria published by Zhan et al.236 or McLeod et al.237 are equally based on the 
Beers criteria. Although similar, the three criteria do not completely agree on the 
drugs that should always be avoided. This demonstrates the problems of defining 
appropriateness of drugs that depends on several factors such as dosage, therapy 
duration, indication, and in particular the individual patient’s clinical condition, 
because physiological functions, e.g. renal function, may markedly vary between 
individual patients in this age group. As the criteria published by Zhan et al. in 
2001236 or McLeod et al. in 1997237 have not been updated since their publication, 
they are not considered superior to the latest Beers criteria published in 2003. 
In the case report a clinically relevant DDI between a selective COX-2 inhibitor, 
rofecoxib, and lithium has been described. In the meantime, rofecoxib, valdecoxib 
and parecoxib, a prodrug of valdecoxib, have been withdrawn from the market in 
2005, because of an increased risk for cardiovascular events including myocardial 
infarction, stroke, peripheral thrombosis and pulmonary embolism and in case of 
valdecoxib and parecoxib also because of severe cutaneous reactions (Stevens-
Johnson syndrome, toxic epidermal necrolysis, erythema multiforme).238-240 
Celecoxib is the only selective COX-2 inhibitor left on the market at the moment. The 
introduction of selective COX-2 inhibitors raised hope that this class would cause 
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less adverse renal effects compared to conventional NSAIDs. However, COX-2 has 
been shown to also play an important role in maintaining renal function such as 
regulation of renal perfusion, salt and water handling and renin release.205 COX-2 
expression is higher in elderly patients and variably induced in conditions such as 
hypertension, congestive heart failure, and diabetic nephropathy.241,242 This might 
explain the increased susceptibility of the kidney to COX-2 inhibitors in patients 
whose renal function is prostaglandin-dependent.205,242 The patient described had a 
chronic renal impairment with a calculated creatinine clearance of 40 mL/min, raising 
the question, if treatment with a selective COX-2 inhibitor was appropriate in this 
case. Initiation of rofecoxib led to an immediate deterioration of renal function and 
accumulation of lithium that is mainly cleared through the kidney. It has been 
described that elderly patients are more vulnerable for neurotoxic effects even at 
serum lithium concentrations, which are considered therapeutic in general adult 
populations (0.4-1.2 mmol/L).223 Summarized, several risk factors predisposed the 
patient for an ADR such as higher age, renal insufficiency, and treatment with lithium, 
a drug with a narrow therapeutic range and exclusively cleared through the kidney. 
Lithium intoxication could have been avoided by selecting paracetamol as analgetic 
treatment, by close therapeutic drug monitoring of lithium concentrations and dose 
adjustment of lithium.  
Based on the potential risk factors for ADRs identified in the review performed at the 
beginning of this thesis and the results of the two projects carried out, as well as 
considering the evidence-based quality indicators developed for the appropriate 
medication use in the Assessing Care of Vulnerable Elders (ACOVE) project, 243,244 
the medication appropriateness index published by Hanlon et al.245 and 
recommendations made in other published articles,5,27,246 the following 
recommendations for a safer drug treatment can be made. A new drug should only 
be prescribed if there is a clear indication. Medical treatment with proven effect and 
established in geriatric medicine should be preferred. However, evidence base for 
prescribing to older people is small, because elderly patients are often excluded from 
clinical trials.14 This makes selecting the right medication and dose for the individual 
older patient often difficult.247 The Beers criteria121 may help to avoid drugs with a 
negative risk-benefit-ratio. It is advised to start with 30-50% of the recommended 
adult dose and to uptitrate the dosage slowly, until the desired clinical effect is 
Discussion, conclusion, outlook 
85 
reached or until ADRs occur.5,15 Dose adjustment should particularly be considered 
for drugs with a high hepatic extraction due to a lower first liver pass effect than 
expected (table 1, page 19) and for renally excreted drugs (table 2, page 22). It has 
to be considered, however, that also accumulation of active metabolites with high 
renal clearance may occur during long-term treatment (e.g. morphine-6-glucuronide). 
Before a new drug is added to an existing drug therapy it should be checked for 
pDDIs (see also table 3, page 26) and drug-disease interactions. Results from the 
first study of this thesis showed that especially drugs used in the treatment of 
arrhythmia and heart failure are often involved in clinically relevant pDDIs. As already 
mentioned, these pDDIs could often be prevented by dose adjustment and/or close 
monitoring. The most common clinically relevant pDDI observed in the study was 
concomitant treatment of ACE inhibitors with potassium sparing diuretics or 
potassium supplements increasing the risk for hyperkalemia. Close monitoring of 
serum creatinine and potassium levels, especially in patients with renal impairment, 
could prevent hyperkalemia.93 For digoxin, as well as for some antiepileptic drugs, 
blood drug concentration measurements are available.27 Amiodarone is mainly 
involved in pharmacokinetic pDDIs and may lead to dose-dependent ADRs by 
inhibiting metabolism of other substances such as oral anticoagulants, atorvastatin or 
simvastatin. Dose reduction and regular monitoring of the international normalized 
ratio (INR) when adding amiodarone to a treatment with oral anticoagulants may 
reduce bleeding risk. In case of a potential drug-disease interaction often alternative 
drugs with a more appropriate drug profile exist. In patients with orthostatic 
hypotension, tricyclic antidepressants may be replaced by SSRIs and, in case of 
antipsychotic treatment, an agent with a low affinity to α1-receptors (e.g. olanzapine, 
quetiapine) may be selected. Long-term use of full-dosage NSAIDs such as 
naproxen, piroxicam or ketoprofen without prophylactic treatment with a proton pump 
inhibitor should be avoided, especially in patients with history of ulcer.40,41 COX-2 
inhibitors are associated with fewer gastrointestinal adverse effects,248 but, as seen 
in the case report, they are no safer than conventional NSAIDs regarding renal safety 
in patients with impaired renal function. Whenever possible, treatment with 
paracetamol should be preferred.40 The combination of drugs with anticholinergic 
and/or sedative properties may increase the risk for cognitive impairment or falls, 
especially in patients with dementia or a history of falls and syncope, and should 
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therefore be replaced by safer alternatives. Clinical benefit has to be assessed within 
6 month after beginning treatment and the drug withdrawn, if the effect is considered 
insufficient despite adequate dosage over an appropriate time period. The possibility 
of an ADR, also resulting from DDIs, has always to be considered, if nonspecific 
complaints such as confusion, lethargy, weakness, orthostatic hypotension, 
dizziness, incontinence, depression, parkinsonian signs and/or falls occur, which may 
be mistaken for ‘geriatric symptoms’.5,89,246 If physicians do not recognize the event 
as drug-induced another drug may be prescribed enhancing the risk for 
polypharmacy, pDDIs and consequently ADRs. It is advised to reevaluate indication 
of a medical treatment from time to time and to review the drug regimen. This may 
reduce the administration of unnecessary drugs and reduce the risk for pDDIs. The 
medication list should always be updated at each visit and also include OTC drugs. 
However, patients should be discouraged to take self-administered drugs. 
Problems of adherence should be addressed in the elderly and drug regimen has to 
be adapted to the patient’s physical and cognitive abilities. Drugs with a simple 
administration schedule are preferred. Generally, once or twice daily drug regimens 
are acceptable. The number of drugs should be kept to a minimum, as poor 
adherence increase with the number of drugs used.21 Although polypharmacy should 
generally be avoided and efforts should constantly be undertaken to reduce the 
number of drugs, one should also be aware of the possible risk to withhold beneficial 
treatments in the elderly.5,162,246 Drugs sometimes not prescribed, but shown to have 
some benefit, include therapy with beta-adrenoceptor antagonist after myocardial 
infarction, antihyperlipidemic drugs, adequate treatment of hypertension, ACE 
inhibitors for heart failure and anticoagulants for nonvalvular atrial fibrillation.5 It is 
further important to check if the drug regimen is practical and if the patients did 
understand the directions given. A pill box may help to improve adherence in case of 
polypharmacy and complex medication regimens. Relatives or caregivers of the 
patients should be involved in the management of pharmacotherapy if the patient is 
seriously ill and/or if cognitive function is impaired. 
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Conclusion 
In this thesis some specific aspects in the medical treatment of elderly patients were 
evaluated increasing the risk for ADRs. In the first study the prevalence of clinically 
relevant pDDIs in dyslipidemic patients treated with a statin and potential risk factors 
were investigated. The prevalence of clinically relevant pDDIs was higher in patients 
aged ≥75 years than in younger patients. Risk factors identified for statin and non 
statin pDDIs in the elderly were polypharmacy, as well as the prescription of drugs 
used in the treatment of arrhythmia and heart failure such as digoxin or amiodarone. 
Because the study was not designed to record ADRs as a result of the pDDIs 
identified, the clinical relevance of the results remains to be elucidated. 
In a second study the prevalence of drugs defined as potentially inappropriate and of 
drugs with anticholinergic properties was assessed in elderly patients hospitalized to 
a medical and geriatric ward. The prevalence of PIMs could be reduced in geriatric 
patients. On the other hand, more benzodiazepines were prescribed to geriatric 
patients with a history of falls or syncope. In addition, drugs with anticholinergic 
properties were often prescribed to medical and geriatric patients. 
The case of lithium intoxication as a result of an interaction with rofecoxib illustrated 
the clinical relevance to assess potential risk factors for ADRs before a new drug 
treatment is initiated, the importance for careful selection of an appropriate treatment 
and of close monitoring, especially when drugs with a narrow therapeutic range are 
given. 
Numerous risk factors may predispose elderly patients to an increased risk for ADRs. 
However, depending on the underlying disease, medical treatment with drugs 
associated with a high potential for pDDIs and/or ADRs may not always be avoided. 
It is therefore important to know pharmacokinetic and pharmacodynamic 
characteristics of the drugs prescribed, including the risk for pDDIs in combination 
with other drugs, to examine the patient’s clinical condition, especially renal function 
and cognitive status, and to prescribe drugs only for confirmed diagnoses in order to 
avoid the prescription of unnecessary drugs. Close monitoring may help to detect 
ADRs early. It has to be considered that they may also manifest as unspecific 
complaints that may be misdiagnosed as ‘geriatric symptoms’. 
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Outlook 
In this thesis only potential risk factors were evaluated, but ADRs following the 
exposure to these risk factors were not investigated. In a next step it would be 
interesting to assess the number of ADRs resulting from pDDIs in elderly compared 
to younger patients. However, depending on the specific ADR evaluated  
e.g. rhabdomyolysis resulting from the combination of simvastatin or atorvastatin with 
CYP inhibitors a high number of exposed patients have to be included in the study 
because rhabdomyolysis is estimated to occur only in 0.04-0.2% of the patients. 
It would also be necessary to evaluate, how many patients develop ADRs due to the 
treatment with PIMs as listed in the Beers criteria. This would help to quantify the risk 
associated with each specific drug listed. It is suggested that in this case also minor 
ADRs should be assessed, because elderly patients are often predisposed to 
multiple risk factors for ADRs, and an additional minor causative factor can already 
lead to the clinical manifestation of an adverse event e.g. delirium or falls. Because 
studies are lacking so far, it would also be interesting to compare the risk of falls 
associated with the use of short-acting benzodiazepines with those of the newer 
compounds such as zolpidem, zopiclone or zaleplon in elderly patients. This would 
provide useful information if these newer compounds are safer than benzodiazepines 
and should therefore be preferred in the treatment of insomnia. 
It would also be interesting to check in an elderly population, if every drug prescribed 
is also indicated based on the diagnoses listed in the medical record. It is suggested 
that the number of drugs could be reduced in many patients, because drugs without 
clear indication are prescribed. In practice, especially at hospital admission the 
medical record could be thoroughly reviewed and unnecessary drugs withdrawn, 
because the patients could be closely monitored for adverse effects resulting from 
withdrawal of these drugs. A clinical pharmacist could assist in the review of the drug 
regimen. Equally, it could also be assessed if a potentially beneficial treatment is not 
given, as undertreatment has also been discussed to occur in the elderly. 
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